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Abstract
Positron Emission Tomography (PET) is an imaging modality that has become
increasingly beneficial in Radiotherapy by improving treatment planning (1). PET reveals tumor
volumes that are not well visualized on computed tomography CT or MRI, recognizes metastatic
disease, and assesses radiotherapy treatment (1). It also reveals areas of the tumor that are
more radiosensitive allowing for dose painting - a non-homogenous dose treatment across the
tumor (1). However, PET is not without limitations. The quantitative unit of PET images, the
Standardized Uptake Value (SUV), is affected by many factors such as reconstruction
algorithm, patient weight, and tracer uptake time (2). In fact, PET is so sensitive that a patient
imaged twice in a single day on the same machine and same protocol will produce different
SUV values. The objective of this research was to increase the capabilities of PET by exploring
other quantitative PET/CT measures for Radiotherapy treatment applications.
The technique of quantitative image feature analysis, nowadays known as radiomics,
was applied to PET and CT images. Image features were then extracted from PET/CT images
and how the features differed between conventional and respiratory-gated PET/CT images in
lung cancer was analyzed. The influence of noise on image features was analyzed by applying
uncorrelated, Gaussian noise to PET/CT images and measuring how significantly noise affected
features. Quantitative PET/CT measures outside of image feature analysis were also
investigated.

The correlation of esophageal metabolic tumor volumes (tumor volume

demonstrating high metabolic uptake) and endoscopically implanted fiducial markers was
studied.
It was found that certain image features differed greatly between conventional and
respiratory-gated PET/CT. The differences were mainly due to the effect of respiratory motion
including affine motion, rotational motion and tumor deformation. Also, certain feature groups
viii

were more affected by noise than others. For instance, contour-dependent shape features
exhibited the least change with noise. Comparatively, GLSZM features exhibited the greatest
change with added noise.
Discordance was discovered between the inferior and superior tumor fiducial markers
and metabolic tumor volume (MTV). This demonstrated a need for both fiducial markers and
MTV to provide a comprehensive view of a tumor.
These studies called attention to the differences in features caused by factors such as
motion, acquisition parameters, and noise, etc. Investigators should be aware of these effects.
PET/CT radiomic features are indeed highly affected by noise and motion. For accurate clinical
use, these effects must be account by investigators and future clinical users. Further
investigation is warranted towards the standardization of PET/CT radiomic feature acquisition
and clinical application.

ix

Chapter One: Introduction1
1.1

Motivation
Lung cancer has the highest estimated death for all cancers in 2015 – causing more

deaths than colorectal, breast, and prostate cancers combined. At 28% for males and 26% for
females, lung cancer deaths lead prostate cancer by 18% and breast cancer by 11% (3). Nonsmall cell lung cancer (NSCLC), the most common type of lung cancer, accounts for 83% of all
lung cancers and 70% of cancers present with advanced or metastatic disease at diagnosis (4).
Typically, early stage NSCLC is treated surgically (stage 1-2)(4). Locally advanced cancers are
typically treated with chemotherapy and concurrent radiation therapy (4). Chemotherapy is
generally prescribed for metastatic disease and palliation. Targeted drugs to improve response
rates (4).
Esophageal cancer accounts for only 4% of estimated deaths for 2015 but the five year
survival rate for esophageal cancer patients is only 18% (3). There are approximately 17,000
estimated new esophageal cancer cases this year alone and almost 16,000 estimated deaths
(3). Most esophageal patients present with locally advanced or metastatic disease. To improve
outcomes, neoadjuvant therapy (chemo-radiotherapy followed by surgery) has been
recommended for patients with locally advanced disease prior to surgery. At present, data on
individual sensitivity to chemotherapy and radiation therapy is lacking, thus patients are advised
to undergo standard of care chemoradiation based on their clinical, rather than molecular,
factors (5). Clinicians rely on radiographic indicators to assess response but, in the absence of
progression at restaging, patients proceed to esophageal resection (surgical removal of the
tumor); the quality of life implications and medical cost are profound if patients have a

1 Portions of this chapter have been previously published in Translational Oncology, 2015, 8(6): 524-534,
and have been reproduced with permission from Elsevier. The author of this dissertation is the first author of the
previously published work. Additional portions of this chapter have been submitted for publication.
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pathologic complete response and yet have undergone removal of their esophagus. Conversely,
if patients are found at the time of surgery to have had no response, their outcomes are no
better than if they went directly to surgery upfront.
For all cancers, diagnostic procedures (such as biopsy) are costly and invasive, and can
be accompanied by severe side effects (6). Image feature analysis is a non-invasive, costeffective technique that extracts tumor identifiers that could lead to more individualized
treatment planning by providing predictive and prognostic biomarkers for cancer patients (7). It
is routine in lung and esophageal cancer for patients to undergo diagnostic PET/CT imaging
prior to initial treatment. In esophageal cancers at our institution (H. Lee Moffitt Cancer Center &
Research Institute) it is also routine for patients to receive endoscopically placed fiducial
markers prior to radiotherapy treatment. These fiducial markers delineate the visible tumor
burden. PET delineates metabolic tumor burden and metabolic metastasis.
New methodologies and techniques to extract quantifiable information from current
technologies (such as image feature analysis) may increase personalized treatment planning
and reduce toxicity by

guiding therapy and monitoring disease progression and treatment

response in lung and esophageal cancers.
1.2

Imaging Modalities
1.2.1

Positron Emission Tomography

Positron Emission Tomography (PET) is a molecular imaging modality that provides
information about the functional biological processes of the body. In radiation oncology, PET is
used in: 1) diagnosis and staging; 2) target definition; and 3) treatment response assessment
(8). In a study by the National Oncological PET Registry, FDG PET was shown to affect patient
management in 36.5% of cases in a study of 22,975 (8).
In cancer imaging, PET can be used to provide information such as tumor heterogeneity,
proliferation, hypoxia, vascular perfusion and angiogenesis, and apoptosis and cellular

2

signaling, depending on the positron emitter used (8). The most common radioactive tracer in
PET imaging for radiotherapy treatment,

18

F-fluorodeoxyglucose (FDG), is used to highlight

areas with high metabolic activity. Tumors are typically characterized by increased FDG uptake
due to increased glycolysis and glucose transport compared to normal tissues (8). Fluorine-18 is
a radioactive isotope that decays via positron emission (97%) and electron capture (3%). This
isotope is substituted for a hydroxyl (OH) group on a glucose molecule at the 2’ position to form
18

F-FDG (Figure 1.1).

Figure 1.1 Molecular structures of glucose and 18F-fluorodeoxyglucose.

The radioactive tracer accumulates in areas of increased glycolysis and glucose
transport (8) – “hot” areas usually include typically tumors, inflammation, brain, and bladder.
After

18

F decays via positron emission, the positrons lose their kinetic energy while travelling a

distance of up to 2.4 mm (Maximal positron range in water. The maximal positron energy is 634
keV (9). Once the kinetic energy is spent, the positron annihilates with an electron producing
two 511 keV gamma rays that travel nearly opposite from each other. Ideally, the rays would
travel at a perfect 180° angle from each other (Figure 1.2). However, these gamma rays are not
always collinear due to scatter. The minimum possible resolution of clinical PET scanners is
1.83 mm full width at half maximum (FWHM) due to the non-collinearity of the gamma rays, the
distance the positron travels before annihilation (10), detector size, and other factors(11). Preclinical PET scanners can have a minimum resolution of 0.67 mm FWHM. At Moffitt Cancer
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Center the minimum PET resolution is 4 mm. The PET/CT scanner at Moffitt Cancer Center is
shown in Figure 1.3 (see page 5).
A ring of detectors surrounding the patient detects the gamma rays and creates a line in
space (line of response) connecting the two interactions. PET detectors are composed of
scintillation crystals (2-3 cm depth) coupled with photomultiplier tubes (9). Scintillation crystals
(commonly bismuth germinate - Bi4Ge3O12 (BGO) or cerium-doped leutium – Lu2SiO5 (LSO))
when struck by incoming gamma rays (511 keV) absorb the energy and scintillate.

Figure 1.2
The PET Mechanism. The patient is injected with 18F-FDG. As positrons are emitted,
each positron annihilates with an electron creating two 511 keV Gamma rays which are detected by the
PET gantry.

Standardized Uptake Value (SUV) is the standard PET measure in image analysis
(equation 1.1).

However, it is clear that SUV is dependent on many technical as well as

physiologic factors (12). It is proportionately dependent upon FDG uptake, which in turn is
affected by dose calibration, clock (decay) synchronization, patient weight and blood sugar
level, documentation of unused tracer remains, and other set-up specifics (12). Moreover, SUV
4

indirectly depends on the method of obtaining raw data, radionuclide uptake time, hardware
platform, and the applied reconstruction algorithm, lesion size, motion, and user region-ofinterest ROI selection (9, 10, 12).
𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑎 𝑣𝑜𝑥𝑒𝑙

𝑆𝑈𝑉 = 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦

⁄𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑚𝑎𝑠𝑠

(1.1)

Studies have shown SUV’s predictive ability of therapy response and survival (13, 14),
although particularly in NSCLC discrepancy remains regarding whether maximum or minimum
SUV is a predictor based on treatment modality (15).The prognostic ability of SUV parameters
has also been shown, but conflict emerges when defining the best cut-off value (13).
Nonetheless, SUV can be unreliable. A clinical study done on the test-retest reproducibility of
SUV demonstrated greater than expected SUV variability within a single institution (12) and
10%-25% SUV variability was detected in a multicenter consortium prior to biological effects or
protocol influences (16). Based on these results and the SUV’s reliance on various nonstandardized factors, it is clear that there is a need for additional indicators that are more robust
than SUV or complementary to SUV-based findings. Quantifiable and robust image features
may be candidates for such indicators.

Figure 1.3

The GE Discovery STE PET/CT Scanner at Moffitt Cancer Center.
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To avoid errors related to radiation attenuation and Compton scattering in the patient
tissue, the patient receives a Computed Tomography (CT) scan prior to the PET scan that acts
as an attenuation map for PET reconstruction (17).
1.2.2

Computed Tomography

CT scanners, though paired with PET scanners are also stand-alone diagnostic imaging
devices and the most commonly used imaging modality for radiation therapy treatment planning.
The first CT scanner was invented in 1972 by Godfrey Hounsfield of EMI Laboratories, England
and Allan Cormack Of Tufts University, Massachusetts. CT scanners were not installed for
clinical use until 1974-1976 (9). These scanners are considered transmission devices (PET
scanners are emission devices). To produce a CT image, x-rays are transmitted through the
body at multiple angles (projections) by rotating an x-ray tube around the body (18). These
images are produced on the order of milliseconds and eliminate the need for many invasive
diagnostic surgeries (9). Because CT images work by absorbing x-rays in tissue they provide
the electron density and are used for attenuation correction in PET images. The electron density
is converted into CT numbers. When normalized with values of -1000 for air, 0 for water, and
more than 1000 for bone, CT numbers are known as Hounsfield Units (equation 1.2) (19).
𝐻𝑈(𝑥, 𝑦, 𝑧) = 1000

(𝜇(𝑥,𝑦,𝑧)−𝜇𝑤 )
𝜇𝑤

(1.2)

where 𝜇(𝑥, 𝑦, 𝑧) is average linear attenuation coefficient for a voxel of tissue at location
(x,y,z) and 𝜇𝑤 is the linear attenuation coefficient for water (9). The relationship between CT
numbers and electron density is nonlinear because of the different atomic numbers of tissues.
This affects whether the Compton or Photoelectric effect is the dominant interaction for beam
attenuation at x-ray energies commonly used in CT. For instance, the relationship between lung
and soft tissue is linear, but the relationship between soft tissue and bone is nonlinear. Because
CT images provide electron densities of tissues, they are used in the dose calculation process
for radiation treatment planning. They provide tissue heterogeneity corrections and are used to
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delineate the target volume (19). CT is used for tumor localization, radiation dose calculation in
radiotherapy planning, and treatment assessment.
1.3

Motion
Due to the relatively long scan time of PET images (2-3 minutes per bed position with 1-

16 bed positions), motion degrades PET images. It affects both the quantification (SUV) and
tumor volume. Because of respiratory motion, there can be an averaging effect in the thoracic
region for PET images (20), resulting in an altered image of the tumor. Conventional or threedimensional (3D) imaging is the most common imaging protocol. During 3D imaging, photon
emission loci are convoluted with anatomical motion. Four-dimensional (4D) imaging accounts
for tumor motion. In this work, we study both 3D and respiratory-gated 4D images (Figure 1.4).

Figure 1.4 Respiratory-gated imaging. Data is binned into phases according to the respiratory cycle. Ten
bins are used in our institution.

Figure 1.4 demonstrates the mechanism of respiratory gated imaging. One method to
accomplish this uses an infrared reflective marker block placed on a patient’s abdomen (an
internal motion surrogate). An infrared revolutions-per-minute (RPM) optical monitor tracks the
location of the marker and associates this with the position of the abdomen at a specific point of
the breathing cycle. Detected events (detected photons) are binned according to the position of
the abdomen at that point on the breathing cycle. This results in one image for each bin (10
images at our institution). These 10 images can be played in cine model thereby demonstrating
tumor motion and deformation over the breathing cycle.
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1.4

Image Noise
According to Hasegawa, “Noise is often defined as the uncertainty in a signal due to

random fluctuations in that signal.”(21) Image noise is caused by a variety of modality specific
factors. PET and CT images possess varying levels of image noise due to the different
mechanisms of detection and image reconstruction. One of the most considerable sources of
image noise (common to both PET and CT), is random variations in photon counting caused by
the statistical nature of x-rays, which is related to the number of photons detected (correlated to
signal and image texture). This is commonly referred to as quantum noise. Electronic noise, or
“dark noise”, is another common source of image noise. This source of noise is inherent to the
detector and independent of the number of photons detected. It is caused by the electronic
components that make up the detector.
CT image noise is mainly random, statistical noise caused by the finite number of x-rays
in projection measurements (22) and the Poisson nature of x-rays (23). In CT, common sources
of noise include body attenuation, detector inefficiency, electronic noise, roundoff errors,
artifacts, and structural noise (density variations in the object). On the other hand, PET image
noise is caused by the random nature of radioactive decay (23, 24). PET images are affected
by partial volume effects, tumor motion, source to background ratio, patient weight, protocol
(three-dimensional or respiratory-gated), and signal loss (e.g., induced by respiratory motion)
(25). Scattering coincidences, random coincidences, and the random corrections degrade the
PET signal-to-noise ratio (SNR). Other contributors of image noise in PET images include:
detectors, electronics and recorder systems, reconstruction algorithms, convolution kernels,
modes of attenuation correction, and radioactive decay correction (26). Electronic noise is a
common source of noise in both PET and CT modalities. This particular source of noise is
considered spatial frequency independent (27). It is typically considered uncorrelated noise.
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Image noise is an unavoidable component of medical imaging. Smoothing filters can be
used to reduce noise, but they cannot eliminate noise completely, and they may also reduce the
signal of interest as well.
1.5

Image Feature Analysis
Texture is a global pattern resulting from repetition of local sub patterns (28). Features

associated with image texture describe the relationships between the gray-scale intensity of
pixels (or voxels in 3D) on a local or global image scale. These features have been used for
classification and segmentation purposes, identifying regions of interest in an image and
estimating heterogeneity (29).
Image features are quite vast in number and can be subdivided into shape features, first,
second, and higher order features. First order features provide information about gray-scale
intensities and are derived from intensity distributions and histograms. Whereas second order
texture features are derived from gray-tone spatial dependency matrices which are constructed
from the intensity value of an image as described below the spatial relationships between voxel
intensities (29, 30). In this paper we refer to all of these as image features.
In medical imaging, CT image texture analysis has been studied extensively, dating back
to the early 1980s (31). More recent studies in CT image analysis have uncovered feature
correspondence with lung tumor aggressiveness and tumor heterogeneity, demonstrated
potential as a marker for survival in NSCLC and revealed relationships between features, tumor
stage, and metabolism (32-34). The reproducibility and robustness of specific identifiers in
NSCLC CT images have also been studied (35).
The application of image feature analysis to PET images has been explored more
recently. Prior studies in PET/CT image texture analysis have demonstrated its potential as a
predictor of tumor and normal tissue response to therapy; a quantifier of tumor heterogeneity
and radiosensitivity; and an indicator for adaptive therapy schemes (13, 36, 37). Conclusive and
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beneficial results regarding tumor response to treatment using multi-modality imaging (38) have
been drawn, and PET texture analysis is currently being explored for application to predictive
models for treatment outcome, partnered with genomics and proteomics patterns (36).
Additionally, various features have been investigated using test-retest and inter-observer
stability in FDG-PET (39). PET image analysis has also been shown to predict response to
radiochemotherapy in esophageal cancer (40) and to quantify tumor heterogeneity as a
response predictor (41). Partnered with a multimodality modeling system, PET texture analysis
could lead to more individualized treatment planning in lung radiotherapy (38).
Moreover, certain FDG-PET-based texture features have demonstrated association with
non-response to chemoradiotherapy for NSCLC tumors (7). These and many other studies are
part of a more general systematic approach, namely radiomics, which is an emerging framework
relating image features to molecular medicine where large amounts of quantitative features
(400+) are extracted for diagnostic, prognostic, and predictive information (36, 42-44). In other
words, PET/CT image feature analysis is an emerging and promising quantitative imaging field.
Although radiomics show much promise, there have been several studies showing
image features dependency on various factors in the production of images. For example, in a
recent study, 45 of 50 texture features showed 10 - 200% variability across acquisition protocols
and reconstruction algorithms (45). Therefore several investigators have pointed to the need for
standardization in texture analysis (46-48).

The usefulness of radiomics depends on the

reliability of feature values, so it is important to characterize feature behavior under many
potential clinical conditions. Our goal in this study was to explore image feature value variability
between respiratory-gated (RG) and conventional (3D) PET images acquired on the same
patient during a single PET scan session as well as to explore the dependence of image
features on image noise.
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1.6

ROI Delineation & Tumor Segmentation
There is a wide variety of methods for ROI delineation and tumor segmentation in PET

imaging (42, 49). A study by Foster et al. reviews the current state-of-the-art PET segmentation
methods (49).

Common segmentation algorithms

in PET

imaging

include: manual

segmentation, threshold based segmentation, gradient or boundary based segmentation,
region-based segmentation, stochastic and learning-based segmentation algorithms, and joint
segmentation methods (49). There is a wide range of opinions about what method is the golden
standard, especially in application to image feature analysis (42) and further research in image
segmentation and agreed-upon metrics is merited (49). A report by the American Association of
Physicists in Medicine (AAPM) TG211 is being composed which analyzes the pros and cons of
the different methods of auto-segmentation in PET.
In this work, we used the fixed threshold method for PET. This method delineates ROIs by
a threshold intensity value or percentage of an intensity value. In radiation oncology, commonly
used PET threshold values of 40-43% of the SUVmax and 2.5 SUV (49). Although standard
thresholding segmentation methods are the easiest to apply, they are not always the most
reliable because of the factors that affect SUV. Factors that will degrade tumor delineation are
patient motion, inter-observer variability, partial volume effect, and noise. These factors affect
any segmentation method because they affect the PET image. However, these factors can
highly affect structures delineated via threshold. Regardless, we deemed the thresholding
method suitable for our study.
1.7

Objectives
The objective of this study was to increase the capabilities and uses of PET/CT in

radiotherapy in lung and esophageal cancers using quantitative techniques such as image
feature analysis. The aims of this work were to: 1) evaluate the effect that motion and
respiratory-gated imaging has on image features; 2) evaluate the effect that uncorrelated noise
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has on image features; 3) evaluate the discrepancies between metabolic tumor volume (MTV)
and fiducials for esophageal tumors.
1.8

Dissertation Structure
Chapter 2 is a review of image feature analysis in lung and esophageal cancers.

Chapter 3 introduces the materials and methods used throughout the study. The method of
segmentation and extraction of image features are described in detail. Chapter 4 explains the
procedure, results and conclusions of the variability of image features computed from
conventional and respiratory-gated PET/CT images of lung cancer. Chapter 5 details
uncorrelated noise effects on image features extracted from conventional and respiratory-gated
PET/CT images of lung cancer. Chapter 6 details the correlation between metabolic tumor
volume and fiducials for locally advanced esophageal cancer. Chapter 7 is a summary of the
work detailed in the dissertation and discussion of possible future work.

12

Chapter Two: Background2
2.1

Image Feature Analysis in PET/CT
Clinical imaging by Positron Emission Tomography (PET) and Computed Tomography

(CT) is evolving into a quantitative discipline where a large number of metrics are computed in
the intensity and gray-level matrix domains; this discipline has been termed Radiomics (42, 50).
The purpose of this dissertation is to review previous studies in image feature analysis and
radiomics applied to Radiotherapy and explore the clinical applications and impact that image
feature analysis can have on patient treatment individualization by elucidating the optimal
treatment method prior to treatment via predictive or prognostic indicators. Radiomics of CT &
PET images have shown promise as a diagnostic, prognostic, and predictive tool in cancer
treatment (42, 51-54). It is also being combined with other “omics” (e.g., genomics,
transcriptomics, proteomics, metabolomics) into decision support systems (55).
2.2

Introduction of the Problem
Lung cancer is the leading cause of death in cancer patients with estimated death rates

of 27% for males and 26% for females in 2016 (56). This rate is higher than both prostate and
breast cancer rates. According to the American Cancer Society, lung and esophageal cancers
have a 5-year survival rate of 17% and 18%, respectively. These are the lowest reported cancer
survival rates (liver and lung are tied for the lowest rate of 17%) (56). It is routine practice for
lung and esophageal cancer patients to receive diagnostic PET/CT images prior to treatment
(57). Image feature analysis offers a non-invasive, cost effective method to extract additional
quantitative data from medical images.

2

Portions of this chapter have been submitted for publication.
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At 18%, esophageal cancer has one of the lowest five-year survival rates of all cancers
and is comparable to that of lung cancer. Recent randomized data supports neoadjuvant
chemoradiation followed by resection for locally advanced disease (58). There are, however,
subsets of patients who are cured with definitive chemoradiation without surgery who thus
successfully undergo organ preservation (59). Clinical validation of sensitivity analyses to
chemotherapy and radiation therapy is ongoing to try to personalize an individual tumor’s
response (5). Standard of care treatment at the present time does not reliably define how to
predict a patient’s likelihood of a complete response to chemoradiation, thus the
recommendation to proceed to surgical resection since even a negative PET/CT (Positron
Emission Tomography/Computerized Tomography) at 6 weeks post treatment can still harbor
residual microscopic disease (60). Accordingly, it has been hypothesized (54) that there are
quantitative imaging methods to determine what treatment regimen will be most suitable for a
particular tumor. The future benefit of such a strategy would be to avoid esophagectomy in
those patients validated to have a clinical complete pathologic response and avoid futile
chemoradiation neoadjuvantly in those patients who do not have sensitive tumors.
A study done by Burton et al. (1998) showed that 44% of all malignant tumors diagnosed
at autopsy were undiagnosed or misdiagnosed. Of these, the top mis- and undiagnosed tumors
were from the respiratory tract (33%) and the gastrointestinal tract (23%) (61). The overall aim
of image feature analysis is to increase the quantitative information about a tumor towards more
personalized treatment. Many investigators try to accomplish this aim by correlating features
with outcomes to be used as predictive or prognostic indicators for more individualized patient
treatment. If predictive or prognostic indicators about a patient’s tumor are available prior to
treatment, then the optimal treatment regimen can be selected prior to treatment. This saves a
patient time, money, gives a better chance of survival, and may spare the patient unnecessary
treatment. For instance, in locally advanced esophageal cancer it is standard-of-care for
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patients to undergo neoadjuvant chemoradiation therapy followed by surgery. If the oncologist
knows prior to treatment that a tumor will not respond to chemoradiation they can recommend
surgery upfront. This saves a patient the pain of undergoing chemoradiation and allowing the
tumor to grow stronger over that period of time while giving the patient their best chance of
survival. Investigators are a long way away from this goal, but a lot of research has been done
in this area in recent years (62).

Figure 2.1. PET coronal image slice, tumor ROI with contour and its grey-level co-occurrence matrix
(GLCM). This is a 2D example for illustration purposes. The GLCM matrix was calculated with Wolfram
Mathematica 9.0 for this illustration (Wolfram Research, Inc., Mathematica, Version 9.0, Champaign, IL
(2012)).

The technique of image feature analysis extracts indicators (features) that provide
information about the heterogeneity, shape, and intensity of a segmented tumor region that is
not traditionally extracted from medical images. These features may also be extracted from
matrices generated from PET/CT images and are known as texture features. Images are
composed of pixels and texture features analyze pixel pairs and pixel areas such as in figure 2.1
(29, 63-65). An example of a matrix is the grey-level co-occurrence matrix (GLCM) where the
number of times 2 pixels with intensity i and j occur adjacent to each other in a particular
direction (29). Other matrices and techniques include: Laws features, Minkowski functionals,
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wavelets, Lapacian transforms and fractal dimensions. These techniques are usually used in the
discipline of radiomics (66).
2.3

Texture Analysis, Image Feature Analysis, or Radiomics?
Although commonly used interchangeably, there is a distinction between texture

analysis, image feature analysis and radiomics. Texture analysis refers to the extraction of
features from an image that provides information on the relationship and patterns between two
or more pixels. In application to tumor images, for example, texture analysis reveals information
about tumor heterogeneity. Texture as defined by Zucker et. al (1980), is a global pattern
resulting from repetition of local subpatterns (28). These subpatterns are directly related to the
intensity values stored in the pixels of the image. Texture analysis was originally created in 1973
by Haralick et al. with the invention of the Grey-Level Co-occurrence Matrix (GLCM) (29). Image
texture describes relationships between pixels (or voxels) on a local or global image scale and
has been used for classification and segmentation purposes (29, 63), identifying regions of
interest in an image and quantifying heterogeneity. Every image is composed of a different
orientation of pixel data and therefore has a different "texture".
Image feature analysis is a broad concept that includes texture analysis, but also
includes shape descriptors and features derived from intensity histograms. Radiomics is an
organized discipline of image feature analysis that extracts large numbers statistically (p<0.05)
of mineable quantitative image features from CT, PET, and magnetic resonance imaging (MRI)
images for decision support. The goal of radiomics is to “convert images into mineable data” –
thus shifting clinical image analysis from a qualitative to a quantitative field (36, 50). Gillies et al.
provided a very detailed description of the current state of radiomics, the challenges and future
of radiomics. Throughout the remainder of this review, features will be spoken of collectively as
image features unless they were specifically named texture features (textural features) or
radiomic features in their respective studies.
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2.4

Clinical Application, Uses, and Relevance of Image Feature Analysis
Image feature analysis of positron emission tomography (PET) and computed

tomography (CT) images has the potential to provide identifiers that may improve treatment
individualization in oncology. It has been studied for application in many aspects of oncology
including chemotherapy, pathology, & radiotherapy. Many studies have demonstrated that
image feature analysis, also known as texture analysis, has predictive or prognostic indicators
(67). This work aims to review various studies which have tested the predictability, repeatability,
and limitations of image feature analysis for lung and esophageal cancer in Radiotherapy
applications. Radiomics as predictive or prognostic biomarkers (66) will also be reviewed.
2.5

Image Feature Analysis in PET
Currently, PET scanners in combination with CT is used for diagnosing patients,

determining cancer stage, and identifying areas of high metabolic activity including the primary
tumor location (68). The Standardized Uptake Value (SUV), which is used for simple semiquantitative analysis, depends on a variety of factors, such as the selected ROI, size of the
tumor, sugar level of the patient, etc (69). Radiation oncologists rely heavily on the SUV value
when analyzing PET for staging. However, studies have shown that SUV values differ across
reconstruction algorithms (45) and from day to day (2).
PET in radiotherapy has improved NSCLC diagnosis of “definite lesions” by 41% (70)
and is also used for dose-painting and tissue sparing. Investigators have applied image feature
analysis in PET to detect heterogeneity indicators in relationship with predictive or prognostic
biomarkers in a number of cancers including non-small cell lung cancer (NSCLC), esophagus,
and cervix. This review focuses mainly on NSCLC and esophageal cancer.
Before the first study on image feature analysis in PET imaging by El Naqa et al. in 2009
(14), clinical image feature analysis was generally applied to CT, MRI and ultrasound images
(71). Since 2009 there has been a burst of interest and investigation in image feature analysis
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applied to PET images. Many studies have identified features that can be used as predictive or
prognostic identifiers for treatment assessment.
2.5.1

Using Heterogeneity as an Indicator in 18F-FDG PET

Many investigators are interested in the application of image feature analysis to 18FFDG PET imaging because it provides a blueprint for the heterogeneity of the metabolic activity
of a tumor. Because of the intrinsic nature of PET, texture pattern within PET tumor images
represents metabolic heterogeneity and biological activity. Since tumors possess characteristic
phenotypes and genotypes, it is believed that tumor heterogeneity provides information about
the radioresistance and aggressiveness of a tumor. Ganeshan et al. (72, 73) demonstrated that
tumor heterogeneity can identify adverse biological features in CT images. However, Cook et al.
(7) resolved that in 18F-FDG PET, these biological correlations are still, to a large extent,
unknown.
El Naqa et al.’s study (14), the first published study on the application of image feature
analysis to PET images, was performed on cervix and head and neck cancers. Although this
study was preliminary, it was the first to suggest that image feature analysis of PET images
could provide better tools and power for use in clinical prognosis. This study also introduced a
new group of features, the intensity-volume histogram metrics. The purpose of the study was to
extract prognostic factors that would be more reliable and informative than SUV statistics
towards the prediction of treatment outcomes. A later study from the same group, by Vaidya et
al., was performed with the purpose of predicting local failure in radiotherapy for NSCLC
patients (38). A total of 32 variables for 27 patients were studied. They found that multimodality
feature modeling provided better performance than single modality features. This finding
supports the current shift towards radiomics studies. These studies will be discussed later in this
report.
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In a study of pre- and post-treatment 18F-FDG PET on patients diagnosed with NSCLC,
small cell lung cancer (SCLC), diffuse large B-cell lymphoma, metastatic papillary renal cell
carcinoma, cerebellar hemongioblastoma, neurofibroma, lymphomatoid granulomatosis, lung
neoplasm, and other cancer types, textural features in combination with SUV measurements
improved the prediction accuracy of morphological changes significantly (74). In this study,
investigators created a framework where tumor regions on PET were automatically segmented.
They found that entropy, max probability, contrast, and SRE were the most valuable features
(74).
A study by Cook et al. investigated the predictive and prognostic abilities of 4 features
from the neighborhood gray-tone difference matrices (NGTDM) for NSCLC patients undergoing
concomitant radiochemotherapy (7). Their features were able to differentiate responders from
nonresponders (defined by CT Response Evaluation Criteria in Solid Tumors (RECIST) (75)).
The textural features performed better than the standard quantitative indicators: metabolic tumor
volume (MTV), total lesion glycolysis (TLG), Standardized Uptake Value (SUV) max, SUV mean
or peak SUV. Overall, Cook et al. found that the abnormal texture in 18F-FDG PET for NSCLC
defined by the features busyness, contrast, coarseness, and complexity from the NGTDM was
associated with nonresponse to chemoradiotherapy by RECIST guidelines and associated with
poorer prognosis (7).
Another study on 18F-FDG PET image feature analysis assessed the relationship
between textural features and SUVmax with histological tumor grade, tumor location and stage
(AJCC). Significant correlations were found between energy and entropy (features derived from
the grey-level co-occurrence matrix, GLCM) and SUV and tumor stage (76).
2.5.2

Tumor Delineation and Volumes

There have also been discrepancies about which tumor delineation method to use for
feature analysis. Currently used segmentation methods include threshold methods, model-
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based methods, and methods that account for background are currently in use. Hatt et al.
studied the robustness of image features across tumor delineation methods and the partial
volume affect (67). They also assessed the predictive value of features with different delineation
methods. They found that the features intensity variability and size zone variability, regional
descriptors from the grey-level size-zone matrix (GLSZM) were the most sensitive to tumor
delineation method and partial volume effect (PVE). Those features that were the most robust
were entropy and homogeneity as well as other local parameters. Zone percentage (ZP) and
high intensity emphasis (HIE) were also robust. There was only a small change in their absolute
or predictive values when classifying patient response to therapy (67).
Another study by Hatt et al. on multi-cancer sites recommended that the minimum
volumes for use in image feature analysis were 10 cc (77).

They also investigated

complementary prognostic values between volume and heterogeneity as well as investigating
the influence of quantization preprocessing and the method of texture feature calculation on
features. They found that most features that have been shown to quantify tumor heterogeneity
are correlated with tumor volume and that prognostic values increased as tumor volumes
increased.
Brooks and Grigsby showed that tumor volume size affects metabolic heterogeneity
studies. They proposed that studies of intratumoral uptake heterogeneity metrics should be
applied to tumors above 45 cc to provide unbiased results (78).
Orlhac et al. investigated the relationship between texture indices, SUV, metabolic
volume, and TLG. They found that the minimum resampling of 32 gray levels should be used for
texture analysis and that many texture features are highly correlated with MTV (79).
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2.5.3

Image Feature Studies Assessing Features as Predictive or Prognostic
Indicators

Many studies have demonstrated the potential for image features as predictive or
prognostic indicators. Chicklore et al. produced an excellent review detailing the studies through
2013 that had been published towards image feature analysis as an indicator for tumor
heterogeneity (13). Tan et al. assessed FDG PET features for predicting pathologic response to
neoadjuvant chemoradiotherapy in esophageal cancer (80). They found that these features
were useful predictors of pathological response to chemoradiotherapy. These features were
found to have the same or higher AUC values than SUVmax and SUVpeak (traditional measures).
Those features were inertia, correlation, and cluster prominence, SUVmean decline, and
skewness pre-CRT (80).
Tixier et al. (40) also studied whether textural features predicted response to
chemoradiotherapy. However, in this case, response was measured using pre and post
treatment CT scans according to the Response Evaluation Criteria in Solid Tumors (RECIST)
rather than the American Joint Committee on Cancer Cancer Staging Manual (6th edition)
pathology as in (80). In this study, features were extracted on a global scale as well as local and
regional levels. The results from this study demonstrated that features were able to differentiate
non-responders from responders. Local homogeneity and entropy were the best identifiers from
the co-occurrence matrix. The best features in predicting response to treatment were intensity
variability and size zone variability, regional descriptors. Not only were these features able to
differentiate non-responders from responders, they were able to distinguish partial responders
from complete responders.
2.5.4 Test-Retest
Although studies have demonstrated that certain features can be used as indicators, it is
important to know if these features are reproducible. There have been a number of test-retest
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studies on image features derived from PET images. These studies are very important to
distinguish those features that can be used clinically with confidence. Leijeneaar et al. tested the
stability of PET radiomics features in NSCLC. The majority of features, 71%, demonstrated high
test-retest stability. Ninety-one percent of features had a high inter-observer stability, as
indicated by the intra-class correlation coefficient. Typically, features with high test-retest
stability also demonstrated high inter-observer stability (39).
A following article by Tixier et al. tested the reproducibility of heterogeneity
characterization via image feature analysis in FDG PET images (41). They tested features
extracted from double baseline FDG PET scans and found that some features had better
reproducibility than traditional factors such as mean and maximum SUV. Interestingly, regional
parameters that characterized larger homogenous areas of high intensity may predict response
to therapy because of high uptake is usually associated with aggressiveness. They suggest that
investigators carefully select their features to provide both a complete and reproducible
characterization of the spatial heterogeneity of tumor FDG uptake (41).
Willaime et al. (37) journeyed away from the traditional PET radiotracer to 18Ffluorothymidine PET (FLT PET), a cell proliferation radiotracer. They assessed if features
extracted from breast cancer PET images could be used to characterize intra-tumor
heterogeneity of in vivo cell proliferation. They also assessed if these features could be used to
predict response to chemotherapy in breast cancer patients. Eight texture features exhibited
variability below 30% and seven of those had reasonably small inter-patient variability. Among
these eight features were entropy (first order), entropy (GLCM), contrast, dissimilarity,
homogeneity.
2.5.5 Limitations and New Approaches
Despite the optimistic results of many previously described studies, there are many
sobering studies which investigate the limitations of image feature analysis in PET. Galavis et
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al. demonstrated that image features are affected by modes of acquisition and reconstruction
parameters (45). After testing 50 features, 45 of 50 demonstrated variability ranging from 10% 200 % between acquisition modes and reconstruction parameters. In a more recent study, Yan
et al. found that image features have different sensitivities to reconstruction settings (81). They
also found that grid size, iteration number and FWHM had an impact on image features with grid
size have the largest impact. An interesting investigation by Chalkidou et al. demonstrated that
PET/CT image feature studies contain a probability of type-I error of 34-99% with an average of
76%. This means that on average, 76% of studies found a false predictive correlation between
features and outcome (82). This is supported by a perspective from Buvat et al. which brings up
other areas that hinder PET image feature analysis such as spatial resolution and noise (71).
Apparently these factors bring their own textural patterns and signal correlation to PET images
(71). Another important factor is anatomical motion during imaging. Oliver et al. investigated the
variability of image features between respiratory-gated and conventional protocols (83) finding
that 26.2 % of PET features had percent differences less than 5% between protocols. Leijenaar
et al. demonstrated that image features are affected by SUV discretization (47) and Nyflot et al.
stressed that additional standardization is needed for PET textural features (48). These and
other investigators call for the standardization of image features.
Cheng et al. alerted investigators that although certain PET features have demonstrated
prognostic significance for certain solid tumors (NSCLC, esophageal squamous cell, cervical
cancer, and oropharyngeal squamous cell), standardization is needed to take PET feature
analysis from the research lab to oncological practice (46). Cheng also resolved that welldesigned multicenter studies in which PET texture features from different institutions could help
with standardization by removing the inconsistencies of PET features (46). Many of which are
caused by differing reconstruction parameters and acquisition modes (45, 46). They also
resolved that one PET textural feature alone will not have accurate information regarding clinical
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outcomes. Instead, groups of multimodal biomarkers should be used since they will have better
prognostic accuracy. This can be achieved through Radiomics (46).
2.6 Image Feature Analysis in CT
CT is the most commonly used diagnostic imaging modality in radiotherapy. It is used for
tumor localization and its unique imaging method provides the electronic density data essential
for treatment planning. CT data are also used for PET attenuation in PET/CT dual modalities.
Image feature analysis in CT images dates back to the 1980s. In recent years, studies have
assessed features derived from CT images towards revealing prognostic phenotypes,
relationships between features, tumor metabolism and stage, and correlations between tumor
hypoxia, angiogenesis, and aggressiveness (32, 34, 73, 84).
Aerts et al. used radiomic features derived from CT images to reveal prognostic
phenotypes in lung cancer and head and neck cancer. The study consisted of 7 independent
datasets - a total of 1019 patients. It was discovered that CT image features have strong
prognostic information associated with gene-expression patterns. They also showed that
radiomic features were complimentary to TNM staging for outcome prediction (84).
A study by Ganeshan et al. demonstrated evidence for a relationship between NSCLC
texture features derived from CT images and tumor metabolism and stage (32). A following
study from the same group tested if tumor heterogeneity, described by texture features from CT
images in NSCLC, were survival markers (33). They found these features to have the potential
to provide independent predictions of survival in NSCLC. Ganeshan et al. also found that
heterogeneity in oesophageal cancers defined by texture analysis of CT images were
associated with increased tumor metabolism and advanced tumor stage (both defined via 18FFDG PET) (72). In a later study, Ganeshan et al. also found that tumor heterogeneity described
using CT image texture in NSCLC had significant correlations with tumor hypoxia markers and
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angiogenesis (73). These studies indicate that features may provide prognostic and functional
information towards personalized treatment in esophageal cancer and NSCLC.
Hunter et al. tested the reproducibility of image features across 3 CT machines from 2
institutions in NSCLC (35). They found that features derived from average 4D CT machines
were the best candidates for correlation in the clinic and had the best reproducibility compared
to end-exhale 4D CT and breath-hold 3D CT (35). This study was modeled after a prior study by
Kumar et al. (85) which demonstrated that the variance for SUV in FDG-PET/CT inside a single
institution was much greater than expected. Relative differences were ±49% for SUVmax and
±44% for SUVmean.
A study by Ravanelli et al. was the first to test whether texture analysis can be used as
independent predictors of chemotherapy response in NSCLC (86). They found that there was
potential for such features as predictive indicators however, a larger study size was needed to
validate the preliminary results. They also created an index, GL*U, composed of two features,
mean grey level and uniformity (32, 33, 72, 86). Texture analysis in CT has also been tested for
its application to radiation-induced lung damage. Ruysscher et al. demonstrated that changes in
Hounsfield Units (HU), the quantitative measure of CT images could identify the entire range of
radiosensitivity on a quantitative scale (87).
The reproducibility of CT image features is a very relevant topic and one that has been
studied by Balagurunathan et al. This group tested the reproducibility of CT image features in
NSCLC (88). Patients received 2 CT scans within a 15 minute period. According to the
concordance correlation coefficient (CCC), certain features were identified with reproducibility
and the ability to predict a prognostic score on the samples (88). Grove et al. (89) developed 2
new robust quantitative imaging features, convexity and entropy ratio. These features were able
to score tumors and identify imaging phenotypes exhibiting survival differences in lung cancer
demonstrating the existing connection between patient survival and features. In future, these
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features may be used diagnostically for lung adenocarcinomas. Image feature analysis of CT
images is not a new topic but the discipline of radiomics is reinvigorating research in this area.
2.7 The Future of Image Feature Analysis
In recent years, networks have been established that encourage the standardization of
quantitative imaging and the sharing of results between researchers, clinical and industry
professionals (90). Two major initiatives, the Quantitative Imaging Network (QIN) and the
Quantitative Imaging Biomarkers Alliance™ (QIBA™), were developed to promote research in
quantitative imaging for clinical trials.
The Quantitative Imaging Network is a framework established to further the development
of quantitative imaging methods and possible biomarkers to measure tumor response in clinical
trials (91). Currently there is an image analysis working group that “provides guidance,
coordination, consensus building, and awareness regarding the development of algorithms and
methods for quantitative analysis.” This working group is composed of dynamic contrastenhanced (DCE)-MRI and PET/CT subgroups.
The Quantitative Biomarkers Alliance (QIBA), sponsored by the Radiological Society of
North America (RSNA) and the National Institute for Biomedical Imaging and Bioengineering
was developed in 2007 by RSNA to promote quantitative image assessment in radiology
through the convergence of researchers, healthcare professionals, and industry. Since that time
they have established a protocol for FDG-PET imaging (90) which provides details from the
beginning: subject handling and image data acquisition, to the end: image interpretation and
reporting, and quality control.
Amongst investigators in image feature analysis, radiomics is considered “the next
frontier in clinical decision making” (66). Gillies et al. stressed the importance of benchmarks for
radiomics studies: extraction, analysis, and presentation of features (66). Radiomics is
becoming the new face of image feature analysis in medical imaging. The annual Radiomics
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Workshop organized by Dr. Gillies from the Moffitt Cancer Center, which began in 2009, has
evolved into a meeting of over 100 investigators from 5 countries and 27 institutions which
encourages the sharing of current radiomic findings and collaboration in the field.
Image feature analysis applied to PET/CT images in lung and esophageal cancer have
proven to have prognostic and predictive indicators that may be used for treatment assessment.
However, studies testing the limitations of these features are underway which will lead to better
standardization and reliability of quantitative image features for decision support.
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Chapter Three: Materials & Methods3
3.1 ROI Delineation and Tumor Segmentation
Throughout this work, image sets were imported and viewed with Mirada Medical
Software (Mirada RTx, Mirada Medical, Oxford, UK), a proprietary software providing tools for
tumor analysis and visualization of Digital Imaging and Communications in Medicine (DICOM)
image data for 3D and RG PET/CT images. The image viewing software provided tumor
visualization, easy access to X, Y, or Z slices of 3D PET data, and region-of-interest (ROI)
delineation.
Segmentation method varied between studies. In Chapter 3, lung tumors are segmented
based on a 40% maximum threshold setting determined by Mirada RTx. PET image tumors
were contoured at 40% maximum intensity inside a defined volume of interest. Tumors on CT
were contoured with CT region segmentation. This method of segmentation was deemed
acceptable for application in this chapter because we were comparing contours from the same
image with differing noise levels.
In Chapters 2 & 4, a background-adapted threshold method of segmentation defined by
Dholakia et al., which accounted for background uptake, was applied to eliminate subjective
errors and inter-observer variability (92). This method involved placing a 3-cm spherical contour
inside the liver and extracting the mean SUV and standard deviation to calculate a threshold
value for the lung tumor (equation 3.1):
𝑀𝑇𝑉𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 = 𝑆𝑈𝑉𝑚𝑒𝑎𝑛 + 2 ∗ 𝑆𝑈𝑉𝑆𝐷

(3.1)

3 Portions of this chapter have been previously published in Translational Oncology, 2015, 8(6):
524-534, and have been reproduced with permission from Elsevier. The author of this dissertation is the
first author of the previously published work. All figures are used with copyright permission. (See
Appendix B).
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where SUVmean is the mean SUV value of the 3-cm sphere and SUVSD is the standard
deviation of the 3-cm sphere's SUV values. This segmentation method will be referred to as the
Dholakia method. We are aware of the many segmentation methods in the literature and that no
one method is generally regarded optimal for general medical applications (49). With lung
tumors, major structures and surrounding tissues were minimal. Consequently there was little
uptake outside the tumor volume. If, however, a tumor was close to the diaphragm or pleura,
nearby metabolic structures were also segmented. Due to the adaptive segmentation method 6
PET lung lesions were rendered too tiny and were not evaluated. In esophageal tumors, the
Dholakia method gave rise to areas of the heart and/or stomach that were included in the
contour. In these cases, a physician-resident reviewed and manually edited these MTVs.
In CT images, tumors were contoured with CT threshold, a proprietary algorithm using
Mirada RTx (see Figure 3.1). The three-dimensional contours were drawn separately on the 3D
CT image and on one phase (phase 1 or phase 10) of the corresponding RG CT image for each
patient. In our clinic, CT contours are used for treatment planning purposes whereas PET
ensures the entire metabolic tumor volume is included in the gross tumor volume (GTV). CT
contours were only collected for lung tumors.
Images were exported from Mirada to a local drive for analysis in DICOM file format.
Structures (contours) were exported from Mirada in DICOM RT file format, an extension of the
DICOM file format. An open source program, RegGui v0.42., in MATLAB (MATLAB and
Statistics Toolbox Release 2012b, The MathWorks, Inc., Natick, Massachusetts, United States)
was used to produce a MetaImage file (.mhd and .raw) using CT images. A MetaImage is a
raw file format, a text-based tagged file format for medical images that stores 3D data in one
file. The .mhd file includes the header information and .raw file includes the data.
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Figure 3.1: CT segmentation of one patient viewed in 2D (the ROI extends in 3D). This CT image is
viewed in the window preset for the lung in Mirada DBx (RTx, Mirada Medical, Oxford, UK).

3.2 Feature Extraction
An internally-developed application imported the ROI data files. We imported .mhd file
format for CT and DICOM file format for PET images, and extracted image intensity statistics,
shape descriptors, co-occurrence matrices, run length matrices, and other second order
features from each ROI for a total of 81 image features (Tables 3.1-3.6). Some groups have
shown the instability of certain features from 3D images (40, 41, 45). Others have used large
numbers of features (>200, (36)). Nevertheless, we deemed 81 features sufficient to assess the
variability between 3D and RG feature values. A total list of image features is listed in Table 3.1.
In PET, the image intensity represented the number of registered counts per voxel,
whereas for CT, intensity represented the Hounsfield Units in each voxel. All intensity levels
were used and normalization was applied only to the co-occurrence and run length matrices (in
the form of binning; 128 bins). Opposite to standard practice, intensity values for PET images
were not converted to SUV. Instead, stored image intensity values were analyzed directly.
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Table 3.1 Extracted Image Features including Shape Features, Intensity Features, GLCM features, RLM features, and GLSZM features.
a

b

Shape (11)

Intensity (22)

GLCM (26)

RLM (11)

Volume (voxels)

Minimum Intensity

Energy

Short Run Emphasis (SRE)

Volume (cc)

Maximum Intensity

Contrast

Surface Area

Mean Intensity

Local Homogeneity

Surface Area/Volume

Peak Intensity

Entropy

Sphericity

Standard Deviation

Correlation

Compactness

Skewness

Autocorrelation

Spherical Disproportion

Coefficient of Variation

Correlation

Long

Kurtosis

Dissimilarity

Short
Eccentricity
Convexity

TGV
RMS
I30
I10-I90
V40
V70
V80
V10-V90
Energy
Entropy
Contrast
Local Homogeneity
Histogram Entropy
Uniformity

Cluster Tendency
Cluster Shade
Cluster Prominence
Mean
Variance
Max Probability
Inverse Variance
Inverse Variance P
Inverse Difference Moment
Inverse Difference
Sum Average
Sum Variance
Sum Entropy
Difference Average
Difference Variance
Difference Entropy
Information Measure of Correlation 1
Information Measure of
Correlation 2

Long Run Emphasis (LRE)
Low Gray-Level Run Emphasis
(LGRE)
High Gray-Level Run Emphasis
(HGRE)
Short Run Low Gray-Level
Emphasis (SRLGE)
Short Run High Gray-Level
Emphasis (SRHGE)
Long Run Low Gray-Level Emphasis
(LRLGE)
Long Run High Gray-Level
Emphasis (LRHGE)
Gray-Level Non-uniformity (GLNU)
Run Length Non-uniformity (RLNU)
Run Percentage (RPC)

a

c

GLSZM (11)
Short Area Emphasis
(SAE)
Large Area Emphasis(LAE)
Low-Intensity Emphasis
(LIE)
High-Intensity Emphasis
(HIE)
Low-Intensity Small-Area
Emphasis (LISAE)
High-Intensity Small-Area
Emphasis (HISAE)
Low-Intensity Low-Area
Emphasis (LILAE)
High-Intensity Low-Area
Emphasis(HILAE)
Intensity Variability (IV)
Size-Zone Variability (SZV)
Zone Percentage (ZP)

Gray-Level Co-occurrence Matrix (GLCM). bRun Length Matrix (RLM). cGray-Level Size-Zone Matrix (GLSZM).

31

3.3 Features
Image features range from shape descriptors to texture descriptors. As previously
described, first order features provide information about gray-scale intensities. These features
are derived from intensity distributions and histograms. Second order texture features are
derived from gray-tone spatial dependency matrices which are constructed from the intensity
value of an image. They describe the spatial relationships between voxel intensities (29, 30).
Second order features provide information about the heterogeneity of a ROI.
Table 3.2 Shape Features
Feature
Convexity
Volume
Surface Area
Surface Area/Volume
Long Axis
Short Axis
Sphericity
Compactness

Description
A measure of the spiculation of
the ROI (ratio of true ROI volume
to convex ROI volume)
A measure of the size of the
tumor in three dimensions.
A measure of the area of the
surface of the tumor volume.
A measure of the surface area
divided by the volume.
A measure of the longest tumor
diameter.
A measure of the shortest tumor
diameter.
A measure of the spherical
shape (roundness) of the ROI
A ratio between the length of the
tumor boundary and the area
(93).

Spherical Disproportion

A measure of the spherical
shape of the tumor.

Eccentricity

A measure of the non-circularity
of the tumor. An eccentricity of 0
is a circle and 1 is a line (14).

Mathematical Description
------3

3
( √𝜋 ∗ √6𝑉 2 )⁄𝐴

3

𝑉 ⁄(√𝜋 ∗ √𝐴2 )
3

𝐴⁄4√𝜋 ∗ √(

3𝑉 2
)
4𝜋

𝑏2
1−√ 2
𝑎

Where a is the semi-major axis and b is the semi-minor axis. V is tumor volume and A is the tumor area.

3.3.1 Shape Descriptors and First Order Features
Shape descriptors and first order features provide contour dependent information about a ROI. Shape
descriptors are calculated directly from the segmented ROI. First order features are extracted from image
intensity statistics and are calculated from volume intensity histograms. A full list and description of the

32

shape descriptors and first order features that were used throughout this work are listed in Tables 3.2 3.4. One particular shape descriptor, convexity, is calculated by taking a ratio of the real convex volume
(a volume created by connecting the furthest tumor edges) to the actual tumor volume. Six first-order
features were based on intensity volume histograms – following the method originally introduced by El
Naqa et al. based on dose-volume histograms (14).

Table 3.3 Intensity and First-Order Features
Feature

Description

Mathematical Description

MinI

Minimum intensity value in the volume-ofinterest(VOI).

𝑀𝑖𝑛(𝐼)

MaxI

Maximum intensity value in the VOI.

𝑀𝑎𝑥(𝐼)

MeanI

Mean intensity value in the VOI.
(The first standardized moment.) (94)

1
∑ 𝐼(𝑣)
𝑁

Variation from the average intensity in VOI.
2
(SD is the second standardized moment.)
(94)

1
√ ∑(𝐼(𝑣) − 𝐼𝑚𝑒𝑎𝑛 )2
𝑁

Skewness

Measures symmetry of the intensity
distribution. (Third standardized moment.)
(94)

1
∑(𝐼(𝑣) − 𝐼𝑚𝑒𝑎𝑛 )3 /𝑆𝐷3
𝑁

Kurtosis

Measures shape of the peak of the intensity
distribution. (Fourth standardized moment.)
(94)

1
∑(𝐼(𝑣) − 𝐼𝑚𝑒𝑎𝑛 )4 /𝑆𝐷4
𝑁

Coefficient of
Variation

A normalized measure of the dispersion of
the VOI. The ratio of the standard deviation
to the mean value of the VOI intensities.

𝜎
𝜇

TGV

Represents the total summed intensity of
the VOI.

∑ 𝐼(𝑣)

SD

𝑁

𝑣=1

𝑁

𝑖=1

𝑁

𝑣=1
𝑁

𝑣=1

𝑁

RMS

𝑣=1
𝑁

The square root of the sum of the squares
of the voxel intensities.

√∑ 𝐼(𝑣)2
𝑣=1
𝑁

Energy

A measure of the homogeneity of the
intensity histogram.

𝑁

∑ ∑ ∑[𝑃(𝑖, 𝑗, 𝑘)]2
𝑖

𝑗
𝐿

Contrast

A measure of the intensity variation of the
intensity histogram.

𝑀

𝑘
𝑁

𝑀

∑ ∑ ∑ 𝑃(𝑖, 𝑗, 𝑘)
𝑖

𝑗

𝑘

Where I(v) is the intensity of a voxel, N is the number of voxels in a volume-of-interest (VOI), and p(i) is the probability of the
occurrence of the grey-level i (37).Where w(i) is the width of the ith bin of the histogram, and TGV is total summed intensity.
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Table 3.3 (Continued)
Feature

Description

Mathematical Description
𝐿

𝑁

𝑀

𝑃(𝑖, 𝑗, 𝑘)
(1 + 𝑖 2 + 𝑗 2 + 𝑘 2 − 𝑗𝑘 − 𝑗𝑘 − 𝑖𝑘)

Local
Homogeneity

Opposite of contrast.

Histogram
Entropy

A measure of entropy of the intensity
histogram of a VOI (95).

𝑝(𝑖)
− ∑ 𝑝(𝑖)log(
)
𝑤(𝑖)

Uniformity

Histogram based assessment of the number
of voxels at each intensity value.

Sum of squares of number of voxels
for each intensity value.

Entropy

A measure of the information content (37).

∑∑∑
𝑖

𝑗

𝑘

𝑁

𝑖=1

−∑

𝑁𝑔

𝑖=1

𝑝(𝑖)𝑙𝑜𝑔2 𝑝(𝑖)

Where I(v) is the intensity of a voxel, N is the number of voxels in a volume-of-interest (VOI), and p(i) is the probability of the
occurrence of the grey-level i (37).Where w(i) is the width of the ith bin of the histogram, and TGV is total summed intensity.

Table 3.4 Additional Intensity and First-Order Features
Feature

Description

I30

Intensity ranging from the lowest 30% to highest intensity volume.

I10-I90

Intensity ranging from lowest to 10% highest intensity volume minus intensity ranging from
lowest to 90% highest intensity volume.

V40

Percentage volume with at least 40% intensity

V70

Percentage volume with at least 70% intensity

V80

Percentage volume with at least 80% intensity

V10V90

Percentage volume with at least 10% intensity minus percentage volume with at least 90%
intensity

I30

Intensity ranging from the lowest 30% to highest intensity volume.

PeakI

Peak intensity in the VOI.

3.3.2 GLCM Features
GLCM features, originally described by Haralick et al, provide texture information about
the spatial relationships of voxels and “summarize the relative frequency distribution” of an
image (29). These features describe relationships between pixel pairs and describe how often a
pixel of gray level i occurs in a defined spatial relationship to a pixel gray level j. A matrix
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containing these relationships is formed in a discrete number of grey level bins (usually 32, 64,
128, or 256). These gray levels are listed on both the row (i) and column (j) of the matrix (see
Figure 3.2). An algorithm counts the number of instances that two pixel intensities are adjacent
to each other in 13 directions. A matrix is created with this data (see Figure 3.2b). Features are
shown in Tables 3.5 and 3.6. Figure 3.2 (see page 37) demonstrates a sample image and
sample GLCM in the 0° direction (horizontal). This image has 5 intensity levels and each
intensity is given its own bin. In the zero direction, the matrix is formed by noting the number of
time pixels of gray level i and j are adjacent. For instance, gray levels 3 and 2 occur in adjacent
pixels twice. The GLCM is a symmetrical matrix and is normalized by dividing each matrix
element by the number of possible pixel pairs, (𝑁𝑥 − 1) ∗ 𝑁𝑦 , where 𝑁𝑥 represents the height
and 𝑁𝑦 represents the width of the image. Thus the GLCM matrix element for (3,2) and (2,3) is
listed as 2/20.

Figure 3.2 (a) Sample figure; (b) Sample GLCM matrix in the 0° direction (horizontal) based on a 5x5
pixel image with 5 grey-levels.
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Feature

Energy

Table 3.5 GLCM Features.
Description

Mathematical Description

Also defined as Angular Second
Moment. This feature describes the
homogeneity of an image. 0 represents
complete heterogeneity. 1 represents
complete homogeneity (96).

𝑁

∑ ∑ 𝑝(𝑖, 𝑗)2
𝑖=1 𝑗=1
𝑁

Entropy

Contrast

Homogeneity

Local
Homogeneity

Correlation

Cluster Shade

Measures the pair contributions and
information content.

Cluster
Prominence

Measures of the skewness of the matrix.
High values = non-symmetry. A peak in
the matrix near mean value = small
variation in gray-scales.

Cluster
Tendency

Measures groups of pixels with similar
intensity values (97).

Mean
(Co-occurrence
Matrix)

The mean value of the co-occurrence
matrix values.

𝑁

∑ ∑ 𝑝(𝑖, 𝑗) log 𝑝(𝑖, 𝑗)
𝑖=1 𝑗=1

Measures local intensity variation. This
favors matrix values that are away from
the diagonal. A value of 0 demonstrates
no contrast.
Measures local intensity variation. This
favors matrix values that are close to the
diagonal. A value of 0 demonstrates
dissimilarity.
Measures the relation of GLCM
intensities to the diagonal GLCM matrix.
A value of 1 represents total
homogeneity. A value of 0 represents
non-homogeneity (96). Also defined as
Inverse Difference Moment.
Measures correlation between cooccurrence matrix values. Measures
gray level linear dependence between
pixels.
Measures of the skewness of the matrix.
High values = non-symmetry

𝑁

𝑁−1

𝑁

𝑁

2

∑ 𝑛 {∑ ∑ 𝑝(𝑖, 𝑗)} , |𝑖 − 𝑗| = 𝑛
𝑛=0

𝑖=1 𝑗=1
𝑁

𝑁

∑∑
𝑖=1 𝑗=1

𝑁

𝑁

∑∑
𝑖=1 𝑗=1

𝑝(𝑖, 𝑗)
1 + |𝑖 − 𝑗|

𝑝(𝑖, 𝑗)
1 + (𝑖 − 𝑗)2

∑𝑖 ∑𝑗(𝑖𝑗)𝑝(𝑖, 𝑗) − 𝜇𝑥 𝜇𝑦
𝜎𝑥 𝜎𝑦
∑ ∑ ((𝑖 − 𝜇𝑖 )
𝑖

𝑗

3

+ (𝑗 − 𝜇𝑗 )) 𝑝(𝑖, 𝑗)
∑ ∑ ((𝑖 − 𝜇𝑖 )
𝑖

𝑗

4

+ (𝑗 − 𝜇𝑗 )) 𝑝(𝑖, 𝑗)
𝑁𝑔 𝑁𝑔

Variance

∑ ∑(𝑖 + 𝑗 − 2𝜇)𝑘 𝑝(𝑖, 𝑗)
𝑖

𝑗
𝑁𝑔 𝑁𝑔

Places high weight on values differing
from the average matrix value.

∑ ∑ 𝑝(𝑖, 𝑗)
𝑖

𝑗

𝑁
𝑁
∑𝑖 𝑔 ∑𝑗 𝑔(𝑖

− 𝜇)2 𝑝(𝑖, 𝑗) +
(𝑗 − 𝜇)2 𝑝(𝑖, 𝑗)

Where p(i,j) is the(i,j)th entry in a normalized grey-level co-occurrence matrix and p(i,j) is the (i,j)th entry in a non-normalized greylevel co-occurrence matrix. N is the number of grey-levels, px is the ith entry obtained by summing the rows of p(i,j). py is the jth
entry obtained by summing the columns of p(i,j). HX and HY are entropies of px and py. GLCM features were originally developed by
Haralick et al. (29, 98).
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Table 3.5 (Continued)
Feature

Description

Dissimilarity

Contrast weighted linearly with the
difference of grey-level values (distance
from diagonal where 0=similarity) (37)

∑ ∑|𝑖 − 𝑗|𝑝(𝑖, 𝑗)

Detects the most frequent pattern (93).
Expected to be high if there is a high
occurrence of the most predominant
pixel pair (97).

𝑀𝑎𝑥𝑖,𝑗𝑔

Max Probability

Mathematical Description
𝑁𝑔 𝑁𝑔

𝑖=1 𝑗=1

𝑁 ,𝑁𝑔

𝑝(𝑖, 𝑗)

Where p(i,j) is the(i,j)th entry in a normalized grey-level co-ocurrence matrix and p(i,j) is the (i,j)th entry in a non-normalized greylevel co-occurrence matrix. N is the number of grey-levels, px is the ith entry obtained by summing the rows of p(i,j). py is the jth
entry obtained by summing the columns of p(i,j). HX and HY are entropies of px and py. GLCM features were originally developed by
Haralick et al. (29, 98).

Table 3.6. Additional GLCM Features.
Feature

Mathematical Description
2𝑁𝑔

∑ 𝑖𝑝𝑥+𝑦 (𝑖)

Sum Average

𝑖=2

2𝑁𝑔

Sum Variance

𝑁𝑔 𝑁𝑔

∑(𝑖 + ∑ ∑ 𝑝(𝑖, 𝑗) log(𝑝(𝑖, 𝑗)))2 log{𝑝𝑥+𝑦 (𝑖)}
𝑖=2

𝑖

𝑗
𝑁𝑔 𝑁𝑔

− ∑ ∑ 𝑝𝑥+𝑦 (𝑖)log{𝑝𝑥+𝑦 (𝑖)}

Sum Entropy

𝑖

𝑗

2𝑁𝑔

∑ 𝑖𝑝𝑥−𝑦(𝑖)

Difference Average

𝑖=2

2𝑁𝑔

Difference Variance

𝑁𝑔 𝑁𝑔

∑(𝑖 + ∑ ∑ 𝑝(𝑖, 𝑗) log(𝑝(𝑖, 𝑗)))2 log{𝑝𝑥−𝑦 (𝑖)}
𝑖=2

𝑖

𝑗
𝑁𝑔 𝑁𝑔

− ∑ ∑ 𝑝𝑥−𝑦 (𝑖)log{𝑝𝑥−𝑦 (𝑖)}

Difference Entropy

𝑖

𝑗

∑∑

Inverse Variance

𝑖

𝑗

∑∑

Inverse Variance P

𝑖

𝑗

𝑃(𝑖, 𝑗)
(𝑖 − 𝑗)2
𝑝(𝑖, 𝑗)
(𝑖 − 𝑗)2

Where p(i,j) is the(i,j)th entry in a normalized grey-level co-ocurrence matrix and p(i,j) is the (i,j)th entry in a non-normalized greylevel co-occurrence matrix. N is the number of grey-levels, px is the ith entry obtained by summing the rows of p(i,j). py is the jth
entry obtained by summing the columns of p(i,j). HX and HY are entropies of px and py. GLCM features were originally developed by
Haralick et al. (29, 98).
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Table 3.6 (Continued)

Feature

Mathematical Description
𝑁

𝑁

∑∑

Inverse Difference

𝑖=1 𝑗=1

𝑝𝑖𝑗
1 + (𝑖 − 𝑗)

𝑁𝑔 𝑁𝑔

𝐻𝑋𝑌 = − ∑ ∑ 𝑝(𝑖, 𝑗)𝑙𝑜𝑔{𝑝(𝑖, 𝑗)}
Information Measure of Correlation 1

𝐻𝑋𝑌1
𝐻𝑋𝑌2 =

𝑖
𝑗
𝑁𝑔 𝑁𝑔
= − ∑𝑖 ∑𝑗 𝑝(𝑖, 𝑗)𝑙𝑜𝑔{𝑝𝑥 (𝑖)𝑝𝑦 (𝑗)},
𝑁𝑔 𝑁𝑔
− ∑𝑖 ∑𝑗 𝑝𝑥 (𝑖)𝑝𝑦 (𝑗)𝑙𝑜𝑔{𝑝𝑥 (𝑖)𝑝𝑦 (𝑗)},,

𝐻𝑋𝑌 − 𝐻𝑋𝑌1
𝑚𝑎𝑥{ℎ𝑥, ℎ𝑦}
2

√1 − e[−2.0(𝐻𝑋𝑌2−𝐻𝑋𝑌)]

Information Measure of Correlation 2

𝑁𝑔 𝑁𝑔

∑ ∑ 𝑖 ∗ 𝑗 ∗ 𝑝(𝑖, 𝑗)

Autocorrelation

𝑖=1 𝑗=1

Where p(i,j) is the(i,j)th entry in a normalized grey-level co-ocurrence matrix and p(i,j) is the (i,j)th entry in a non-normalized greylevel co-occurrence matrix. N is the number of grey-levels, px is the ith entry obtained by summing the rows of p(i,j). py is the jth
entry obtained by summing the columns of p(i,j). HX and HY are entropies of px and py. GLCM features were originally developed by
Haralick et al. (29, 98).

3.3.3 Run Length Matrix Features
The Run Length Matrix (RLM) was originally introduced by Galloway (64). The RLM is a
matrix consisting of dimensions LxR where L is the number of grey levels and R is the number
of possible runs. A run is a set of adjacent voxels that possess the same grey level in a
particular direction. A sample RLM is demonstrated in Figure 3.3. The RLM consists of 5
traditional features proposed by Galloway (64), 2 features proposed by Chu et al. (99), and 4
features proposed by Dasarathy and Holder (100). These features are introduced in Table 3.7.
Figure 3.3 demonstrates a sample image and sample RLM in the 0° direction (horizontal). This
image has 5 intensity levels. The gray level 3 occurs in a run 1 pixel long 4 times. Thus, the
GLCM matrix element (R,L) for (3,1) is 4.
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Figure 3.3 (a) Sample Image; (b) RLM Matrix calculated based on sample image with 5 grey levels in the
0° direction.

3.3.4 Grey Level Size Zone Matrix Features
The Grey Level Size Zone Matrix (GLSZM) was developed by Thibault (63, 101)
according to the run length matrix principle. This principle states that the value of matrix z(i,j)
equals the number of zones of size i and gray level j (101). The GLSZM is different from the run
length matrix in that it examines “zones” instead of “pairs”. It records the size of groups of
adjacent pixels containing the same intensity levels (see Figure 3.4). GLSZM features are
analogs of RLM features and are described in Table 3.8. Figure 3.4 demonstrates a sample 2D
image and sample GLSZM. Because the GLSZM measures zones it does not need to be
measured in any particular direction. Each direction will produce the same GLSZM. The sample
image has 5 intensity levels. GLSZM matrix element (2,1) has a value of 3 because the gray
level 2 has a size of 1 in 3 instances.
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Feature

Table 3.7 RLM Features
Description

Mathematical Description
𝑀

a

SRE

a

LRE

b

LGRE

b

HGRE

c

SRLGE

c

LRLGE

c

SRHGE

c

LRHGE

RLNU

a

GLNU

RPC

a

a

𝑁

Measures short run distribution; (short run
emphasis).

1
𝑅(𝑖, 𝑗)
∑∑ 2
𝑛
𝑗

Measures long run distribution; (long run
emphasis).

1
∑ ∑ 𝑅(𝑖, 𝑗)𝑗 2
𝑛

Measures low grey-level distribution; (low greylevel run emphasis).

1
𝑅(𝑖, 𝑗)
∑∑ 2
𝑛
𝑖

Measures high grey-level distribution; (high greylevel run emphasis).

1
∑ ∑ 𝑅(𝑖, 𝑗)𝑖 2
𝑛

Measures short runs and low grey-level
distribution; (short run low grey-level emphasis).

1
𝑅(𝑖, 𝑗)
∑∑ 2 2
𝑛
𝑖 𝑗

Measures long runs and low grey-level
distribution; (long run low grey-level emphasis).

1
𝑅(𝑖, 𝑗)𝑗 2
∑∑
𝑛
𝑖2

Measures short runs and high grey-level
distribution; (short run high grey-level emphasis).

1
𝑅(𝑖, 𝑗)𝑖 2
∑∑
𝑛
𝑗2

Measures long runs and high grey-level
distribution; (long run high grey-level emphasis).

1
∑ ∑ 𝑅(𝑖, 𝑗)𝑖 2 𝑗 2
𝑛

Measures the non-uniformity of the run lengths;
(run length non-uniformity).

1
∑ (∑ 𝑅(𝑖, 𝑗))
𝑛

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑀 𝑁

𝑖=1 𝑗=1
𝑁

𝑀

𝑖=1

𝑗=1

𝑀

𝑁

𝑗=1

𝑖=1

Measures the non-uniformity of the grey-levels;
(grey-level non-uniformity).

1
∑ (∑ 𝑅(𝑖, 𝑗))
𝑛

Ratio of total number of runs to total number of
pixels in the image. Measures homogeneity and
run distribution; (run percentage).

𝑛
𝑛𝑝

b

2

2

Where R(i,j) is an element of the Run Length Matrix, n is the total number of runs, np is the number of pixels in the image, N is the
longest run and M is the number of grey levels. aRLM features developed by Galloway et al. (64). bRLM features developed by Chu
et al. (99). cRLM features developed by Dasarathy and Holder (100).
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Figure 3.4 (a) Sample Image; (b) Sample GLSZM Matrix based on sample image with 5 grey levels.

Table 3.8 Gray-Level Size-Zone Matrix Features.
Feature

Description

Mathematical Description
𝑚

Small-area emphasis
(SAE)

Emphasizes small areas

𝑛 𝑧(𝑖, 𝑗)
1
∑∑
2
Ω
𝑗=1 𝑗
𝑖=1

𝑚

Large-area emphasis

Emphasizes large areas

𝑛
1
∑ ∑ 𝑗 2 , 𝑧(𝑖, 𝑗)
Ω
𝑗=1
𝑖=1

𝑚

Low-intensity emphasis

Emphasizes low intensity
areas.

𝑛 𝑧(𝑖, 𝑗)
1
∑∑
2
Ω
𝑗=1 𝑖
𝑖=1

𝑚

High-intensity emphasis

Emphasizes high intensity
areas

𝑛
1
∑ ∑ 𝑖 2 , 𝑧(𝑖, 𝑗)
Ω
𝑗=1

Emphasizes small areas with
low intensity

𝑛 𝑧(𝑖, 𝑗)
1
∑∑
2 2
Ω
𝑗=1 𝑖 , 𝑗

𝑖=1

𝑚

Low-intensity small-area
emphasis

𝑖=1

𝑚

High-intensity small-area
emphasis

Emphasizes small areas with
high intensity

𝑛
1
∑ ∑ 𝑖 2 , 𝑗 2 , 𝑧(𝑖, 𝑗)
Ω
𝑗=1

Low-intensity large-area
emphasis

Emphasizes large areas with
low intensity

𝑛 𝑗 2 , 𝑧(𝑖, 𝑗)
1
∑∑
Ω
𝑖2
𝑗=1

𝑖=1

𝑚

𝑖=1

Where z(i,j) is the (i,j)th entry in the z matrix, Ω is the number of homogeneous areas, n is the number of distinct intensity values
within the tumor and m is the size of the largest homogeneous area in the z matrix (101).
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Table 3.8 (Continued)
Feature

Description

Mathematical Description

High-intensity large-area
emphasis

Emphasizes large areas with
high intensity

𝑚

𝑛
1
∑ [∑ 𝑧(𝑖, 𝑗)]
Ω
𝑗=1

2

𝑖=1
𝑚

Intensity variability

Variance of intensity levels

𝑛 𝑖 2 , 𝑧(𝑖, 𝑗)
1
∑∑
Ω
𝑗2
𝑗=1
𝑖=1

Zone Percentage

A ratio between the number of
zones and the total number of
voxels (total possible zones)

𝑚

𝑖=1
𝑚

Size-zone variability

Variance of the size-zone

𝑛

Ω ⁄∑ ∑

𝑗=1

𝑗 2 , 𝑧(𝑖, 𝑗)

𝑛 𝑧(𝑖, 𝑗)
1
∑ [∑
]
2
Ω
𝑗=1 𝑖

2

𝑖=1

Where z(i,j) is the (i,j)th entry in the z matrix, Ω is the number of homogeneous areas, n is the number of distinct intensity values
within the tumor and m is the size of the largest homogeneous area in the z matrix (101).
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Chapter Four: Variability of Image Features Computed From Conventional and
Respiratory-Gated PET/CT Images of Lung Cancer4
4.1

Introduction
Positron Emission Tomography (PET) is a beneficial technology in the process of cancer

diagnosis and staging (102, 103), monitoring tumor response to treatment (104), detecting
necrosis and tumor heterogeneity, identifying the primary tumor location (68), and delineating
tumors from atelectasis (105), particularly in lung cancers. In fact, studies have shown that the
use of PET/CT improves confidence in diagnosis, increases the number of “definite” lesions by
41% in patients with Non-Small Cell Lung Cancer (NSCLC) (70) and improves delineation
accuracy for gross tumor volumes (GTV) in radiation therapy (68, 105).
Conventional (3D) PET images are influenced by motion because of their relatively long
acquisition times. The acquired coincidence counts measured and used to form the images are
spatiotemporally averaged over multiple breathing cycles (106), consequently, for a point inside
a mobile tumor the signal is convoluted along its trajectory of motion. Respiratory-gated PET/CT
aims to account for respiratory motion and thereby respiration-induced image blurring. One way
to discern the effect of motion on feature values is by comparing image feature values between
conventional and respiratory-gated acquisition protocols, although other important factors
stemming from the differences in the imaging protocols such as image noise are also at play.
Thus far, only one study accounting for motion in PET images has been reported by Yip et al.
(107), which was limited to only 5 features. This report represents the first study that evaluates
how 3D and RG acquisitions affect a large number of image features currently being used and

4 Portions of this chapter have been previously published in Translational Oncology, 2015, 8(6): 524-534,
and have been reproduced with permission from Elsevier (see Appendix B). The author of this dissertation is the first
author of the previously published work. All figures are used with copyright permission.
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tested in several medical applications. Robust features that emerge from this study may be
suitable candidates for future quantitative imaging applications involving mobile tumors.
4.2

Materials and Methods
4.2.1

Preliminaries

Twenty-three lung cancer patients were retrospectively selected for a study of image
feature variation between 3D & RG (RG is alternatively known as 4D) PET/CT images, and
feature value variation among the 10 phases of a respiratory-gated scan. The main selection
criterion was for these patients to have both 3D and RG PET/CT scans performed during the
same imaging session. The 3D images were acquired in free breathing conditions for patients
with regular breathing as required for Radiotherapy planning. There were thirteen female and
ten male patients ranging from age 47 to 83. All lung cancer patients were diagnosed with NonSmall Cell Lung Cancer (NSCLC). For each patient,

18

F-FDG was the administered radiotracer

and the respiratory-gated PET scan was acquired during the same session as the 3D PET scan
in the same position per protocol for radiation treatment planning. A radiologist approved 4D
PET/CT protocol was applied for image acquisition (108). The 3D PET/CT protocol was adapted
for our institution from the Netherlands Protocol (109). In routine clinical practice following these
protocols, the average scan start times after the tracer administration were 118 ± 17.3 minutes
(standard deviation) for 3D PET and 117 ± 36.0 minutes for RG PET with average administered
activity of 11.9 ± 2.0 mCi. A study on SUV variance in clinical FDG-PET/CT found that SUVmax
and SUVmean were independent of variations in the uptake period (85).
PET/CT data were obtained using a GE Discovery STE PET/CT Scanner (for 21 cases)
and a GE Discovery 600 PET/CT Scanner (for 2 cases). The 3D CT was a standard step and
shoot CT (not helical) and the respiratory-gated PET counts were binned into 10 phases with 3D
CT attenuation correction applied to 4D PET data (standard protocol at our institution). The
standard reconstruction protocol was the ordered subset expectation maximization (OSEM)
algorithm with 20 or 28 subsets and 2 iterations. Full width at half maximum (FWHM) and field
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of view (FOV) varied between patients: full width at half maximum of 4.29 mm, 7 mm or 10 mm,
and field of view of 50, 60 or 70 cm were standard PET settings. Standard of practice
procedures at our institution were followed and this study was approved with waived informed
consent by the University of South Florida Institutional Review Board.
4.2.2

ROI Delineation and Tumor Segmentation

Following patient selection, the tumor region was identified using an advanced image
viewing software (Mirada RTx, Mirada Medical, Oxford, UK), allowing identification of the
primary tumor location and exportation of Digital Imaging and Communications in Medicine
(DICOM) image data for 3D and RG PET/CT images. The image viewing software provided
tumor visualization, easy access to X, Y, or Z slices of 3D PET data, and region-of-interest
(ROI) delineation. A background-adapted thresholding method of segmentation defined by
Dholakia et al., which accounted for background uptake, was applied to eliminate subjective
errors and inter-observer variability (92). This method involved placing a 3-cm spherical contour
inside the liver and extracting the mean SUV and standard deviation to calculate a threshold
value for the lung tumor (Equation 4.1):
𝑀𝑇𝑉𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 = 𝑆𝑈𝑉𝑚𝑒𝑎𝑛 + 2 ∗ 𝑆𝑈𝑉𝑆𝐷

(4.1)

where SUVmean is the mean SUV value of the 3-cm sphere and SUVSD is the standard
deviation of the 3-cm sphere's SUV values. We are aware of the many segmentation methods
in the literature and that no one method is generally regarded optimal for general medical
applications (49). Since we were working with lung tumors, major structures and surrounding
tissues were minimal. Consequently there was little uptake outside the tumor volume. If,
however, a tumor was close to the diaphragm or pleura, nearby metabolic structures were also
segmented. Due to the adaptive segmentation method 6 PET lesions were rendered too tiny
and were not evaluated.
In CT images, tumors were contoured with CT threshold, a proprietary algorithm using
Mirada RTx (RTx, Mirada Medical, Oxford, UK) (see Figure 2.1). The three-dimensional
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contours were drawn separately on the 3D CT image and on one phase (phase 1 or phase 10)
of the corresponding RG CT image for each patient. In our clinic, CT contours are used for
treatment planning purposes whereas PET ensures the entire metabolic tumor volume is
included in the gross tumor volume (GTV).
4.2.3

Feature Extraction

An internally-developed application imported the ROI data file and extracted image
intensity statistics, shape descriptors, co-occurrence matrices, run length matrices, and other
second order features from each ROI for a total of 56 image features. Although some authors
have shown the instability of certain features from 3D images (40, 41, 45), we decided to
include them here to analyze their stability for RG images. Moreover, some groups have used a
large number of features (>200; (36)). Nevertheless, we deemed 56 features sufficient to
assess the variability between 3D and RG feature values.
Shape descriptors were calculated directly from the segmented ROI. First order features
(extracted from image intensity statistics) were calculated from volume intensity histograms.
Second order grey-level co-occurrence matrix (GLCM) features, originally described by Haralick
et al. (29, 98) were implemented with feature descriptions provided by Liang (96). The Haralick
definition of second order statistics (based on grey-level matrix metric), nearest neighbor spatial
dependence matrices, provided texture information from the spatial relationship of image voxels
(29).
The GLCM feature calculations were implemented as follows: the intensities of image
voxels were binned into 256 gray-scale levels for PET (128 gray-scale levels for CT) with equal
intervals. The resulting 2D co-occurrence matrix was 256 x 256 (128 x 128) with unit (1) pixel
distance. Co-occurrence matrices were calculated in 13 directions across a 3D image and the
resultant matrix was the average of the matrices in the 13 directions. Given a set of cubical
voxels, the 13 directions were: 3 axial directions, 2 diagonal directions per axial plane × 3 axial
planes, and 4 diagonal directions cross cube (110). These 13 directions were chosen so that the
46

resulting matrix would represent the entire tumor texture without bias. The elements of the
matrix were integers. Next, a probability matrix was calculated by dividing each element by the
total sum of the matrix so that the sum of the probability matrix was 1. The features were then
calculated using the probability matrix.
Galloway’s original run length features were also implemented (64). Feature definitions
were acquired from Galloway, Chu et al., and Dasarathy and Holder (64, 99, 100). The run
length matrix (RLM) had dimensions of L x R, where L was the number of grey-scale levels (256
for PET; 128 for CT) and R were the possible runs (determined case-by-case). The elements of
the matrix were integers which represented runs. A run was defined as a set of pixels that
possessed the same gray level in a specified direction (111). The RLM was calculated in 13
directions across an image (similar to the co-occurrence matrix) (112). The feature values were
the summed values of all 13 directions normalized by the total runs in each direction. No
probability matrix was involved for the run-length features.
In PET, the image intensity was the number of registered counts per voxel. For CT,
intensity represented the Hounsfield Units in each voxel. All intensity levels were used.
Normalization was applied only to the co-occurrence and run length matrices (in the form of
binning; 128 bins). Additionally, intensity values for PET images were not converted to SUV.
Instead, stored image intensity values were analyzed directly. For each patient, image features
were extracted from the 3D PET ROI, 3D CT ROI, all phases (bins) of the respiratory-gated PET
ROI, and one phase (bin) of the respiratory-gated CT ROI.
Following feature extraction, 3D and RG PET/CT image feature differences were
calculated using Equation 4.2,

%𝐷𝑖𝑓𝑓𝑖

3𝐷/𝑅𝐺

=

|𝑅𝐺𝑇𝑉𝑖 −3𝐷𝑇𝑉𝑖 |
𝑀𝑎𝑥(|𝑅𝐺𝑇𝑉𝑖 |,|3𝐷𝑇𝑉𝑖 |)

(4.2)

where RGTVi is the respiratory-gated image feature value for feature i and 3DTVi is the
3D image feature value for feature i. This method was chosen because it accounts for features
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that changed sign between 3D and RG cases. The maximum possible percent difference using
Equation 2 is 200% and differences greater than 100% were deemed large. The percent
difference across cases was then averaged for each image feature and a paired, two-tailed ttest was applied to 3D and RG feature data to compare the two datasets. We assumed normal
distributions and that the t-test was applicable. The concordance correlation coefficient (CCC)
was calculated for all features across 3D and RG feature data to determine the correlation
between the two datasets. The scale used for determining strength-of-agreement was as
follows: high strength-of-agreement – CCC > 0.99, substantial strength-of-agreement – CCC:
0.95-0.99, moderate strength-of-agreement – CCC: 0.90-0.95, poor strength-of-agreement –
CCC < 0.90 (113).
4.2.4

RG (4D) PET Phase Analysis

The previously described procedure of image feature extraction was applied to all
respiratory-gated PET bins. Mean percent difference was used to compare features between
phases,
%𝐷𝑖𝑓𝑓𝑖𝑗𝑀𝑒𝑎𝑛 = |

(𝑇𝑉𝑖𝑗 −𝜇𝑇𝑉,𝑗 )
𝜇𝑇𝑉,𝑗

|

(4.3)

where i represents the bin, j represents the specific image feature, TVij represents the
value for bin i and feature j, and µTV,j represents the mean value for image feature j. Image
feature values were also normalized by average value across all bins,

𝑁𝑜𝑟𝑚𝑉𝑎𝑙𝑢𝑒𝑖𝑗 =

𝑇𝑉𝑖𝑗
𝜇𝑇𝑉,𝑗

(4.4)

The subscript definitions for Equation 4.3 also apply to Equation 4.4. Additionally, a
paired, two-tailed t-test was applied to RG inhale (phase 1) feature data and RG exhale (phase
5) feature data to compare the two datasets. The CCC was calculated for phase 1 and phase 5
of the feature data to determine correlation between the two datasets.
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4.2.5

Long Axis Calculation and Rotation Analysis

The long axis length (through the center of mass) was calculated with an internallydeveloped program for each bin of the respiratory-gated cycle (PET only). The tumor’s center of
mass location was calculated for the inhale and exhale phases of the respiratory-gated PET
image sets (Equation 4.5).
𝐶𝑀(𝑥, 𝑦, 𝑧) = [

∑𝑖 𝐼𝑖 𝑥𝑖 ∑𝑖 𝐼𝑖 𝑦𝑖 ∑𝑖 𝐼𝑖 𝑧𝑖
, ∑ , ∑ ]
∑𝑖 𝐼𝑖
𝑖 𝐼𝑖
𝑖 𝐼𝑖

where 𝐶𝑀(𝑥, 𝑦, 𝑧)is the center of mass for a tumor in a PET phase and

(4.5)

Ii

is the number

of counts per voxel i. The center of mass motion (CMM) was calculated as the displacement
between the center of mass for inhale phase and center of mass for exhale phase. The
difference in long axis length and CMM were used to assess changes in internal tumor
morphology. Tumor angle was defined as the angle between the long axis of the tumor and the
XY plane (see Figure 4.1). A Pearson’s correlation test was applied to identify correlation in
tumor angle and long axis length between inhale and exhale images.
4.3

Results
4.3.1

3D and RG PET/CT Image Feature Analysis

Features from both PET and CT images demonstrated dependency on whether the
acquisition was 3D, which is conventional (also called static), or respiratory-gated, (RG or 4D),
where the coincidence counts are binned in multiple phases/bins composing the respiratory
cycle. Large differences in some features were found between 3D PET/CT and one of the
phases/bins of the corresponding respiratory-gated data set. The percent differences between
3D and respiratory-gated modalities were usually larger for CT than for PET. For PET, 10 of 56
features had a percentage difference (between 3D PET and RG PET for each patient) of less
than 5% for more than half of the cases. In comparison, 11 of 56 CT features had a percentage
difference (between 3D CT and RG CT for each patient) of less than 5% for more than half the
cases. The percent differences between 3D PET and RG PET varied from 0% to 193%. The
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outlier of 193% was kurtosis. For 4 of 17 cases, kurtosis demonstrated the greatest percent
difference between 3D and RG PET. Image feature average differences between 3D PET and
RG PET are shown in Table 4.1.

Figure 4.1 Method of tumor rotation calculation. First, the tumor volume is delineated at exhale (phase 1)
and inhale (phase 5) on RG PET images. Second, the center of mass of each volume is calculated. The
long axis length (longest diameter) through the center of mass of the tumor is calculated. Then, the angle
between the long axis length and the XY-plane is calculated. This angle is compared between the exhale
(phase 1) and inhale (phase 2) to determine the pseudo-tumor rotation.

Percent differences between 3D CT and RG CT varied from 0% to 176%; kurtosis again
being the outlier. Figure 4.2 shows selected feature percent differences and Table 4.2 shows
image feature average differences between 3D and RG CT. Forty-six percent of the CT features
between 3D CT and RG CT presented average percent differences larger than 20%. In some
cases average percent differences were larger than 50%. Table 4.3 displays the number and
percent of total features with specific percent differences for CT, PET, and PET RG phases.
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3D/RG

Figure 4.2 Average differences between 3D and Respiratory-Gated Image Features. %Diffi
selected image features from 3D PET/CT and RG PET/CT.

between

Table 4.1 Features Presenting Average Differences Between 3D and RG PET Image Features.

<2%
Difference

<5%
Difference

<10%
Difference

<15%
Difference

<20%
Difference

SRE

Sphericity

Surface
Area/Volume

Volume

V10-V90

Spherical
Disprorportion

Compactness

Surface Area

Entropy (1st
order)

Convexity

Long Axis

Information
Measure of
Correlation 2

Entropy
(2nd order)

Short Axis

Sum Average

TGV

RPC

Sum Entropy

Local
Homogeneity
(1st order)
Difference
Average
Difference
Variance

Information
Measure of
Correlation 1

RMS

Difference
Entropy

Contrast
(1st order)
Cooccurrence
Mean

>50%
Difference
Minimum
Intensity
Mean
Intensity
Kurtosis

I30
I10-I90
LRLGE
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Table 4.2 Features Presenting Average Differences Between 3D and RG CT Image Features.

<2%
Difference

<5%
Difference

Minimum
Intensity
SRE

Mean
Intensity
RMS

<10%
Difference
Convexity
LRE

<15%
Difference
Surface
Area/Volume
Sphericity

<20%
Difference

>50%
Difference

Volume

Kurtosis

SD
Coefficient of
Variation

TGV

I30

Compactness

RPC

Spherical
Disproportion

I10-I90

V80

Difference
Entropy

Local
Homogeneity
(2nd Order)

Energy (1
Order)

Sum Average

V70

st

Cluster
Shade
Cluster
Prominence
Cooccurrence
Mean
Cooccurrence
Variance
GLNU
RLNU

Overall, 249 of 952 (26.2%) of all PET features (56 features per patient) had a percent
difference of less than 5% between 3D and RG protocols whereas, 342 of 1288 (26.6%) of all
CT features (56 features per patient) had a percent difference of less than 5% between 3D and
RG scans. Table 4.4 shows features that had percent differences between 3D and RG protocols
for all cases for both PET and CT modalities.
3D/RG

Table 4.3 Percent Differences (%Diffi
) between Image Features of 3D and RG, PET and CT Images
and Conglomerate Image Features of RG PET phases for all cases (%𝐃𝐢𝐟𝐟𝐢𝐣𝐌𝐞𝐚𝐧 ).
CT
Percent
Difference
<5%
<10%
<15%
<20%
>20%

No. of
a
Features
(1288
total)
342
498
617
697
591
a

% Total
a
Features
26.6%
38.7%
47.9%
54.1%
45.9%

PET
PET RG Phases
No. of
No. of
% of
a
a
Features
% Total Features
Total
a
(952
Features
(9464
a
Features
total)
total)
249
26.2%
5051
53.4%
405
42.5%
7258
76.7%
515
54.1%
8043
85.0%
585
61.4%
8410
88.9%
367
38.6%
998
10.5%

Total number of features refers to 56 image features per tumor.
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According to the CCC strength-to-agreement scale by McBride et al., PET and CT
feature subtypes demonstrated poor correlation between 3D and RG images (113) (see Figure
4.3). This was demonstrated by CCC strength-to-agreement values less than 0.90 for each
feature subtype (shape, first order, GLCM, and RLM). However, there were specific features
that demonstrated substantial strength-of-agreement. These were from the shape and first-order
features in PET and shape features only in CT.
Table 4.4 Image Features with Common Average Differences in 3D/RG PET and CT.
Percent Difference

Common Features

<2%

SRE

<5%

<20%

-Convexity, 1 and 2 order Entropy, Sum Entropy, LRE,
RPC
Surface Area/Volume, Sphericity, Compactness, Spherical
Disproportion, Difference Entropy, Information Measure of
Correlation 2
Volume, Long Axis Length,V10-V90, Sum Average

>50%

Kurtosis, TGV

st

<10%
<15%

nd

Figure 4.3 Concordance correlation coefficients for each feature with mean and standard deviation for
each feature subtype for (A) 3D/4D CT and (B) 3D/4D PET.

The paired, two-tailed, t-test for 3D PET and RG PET features revealed 17 PET features
with p values <0.05 (indicating that these datasets are different). The t-test for 3D CT and RG
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CT features revealed 12 CT features with p values <0.05. Features with p values <0.05 for both
PET and CT were entropy (1st order), compactness, and information measure of correlation 1
and 2.
4.3.2

RG (4D) PET Phase Analysis

Results indicated a weak dependency (relative to the differences between 3D and RG
presented above) of all PET features on respiration phase in RG scans of 10 phases (see
Figure 4.4). The most robust features (less than 5% difference among RG phases) belonged to
select features from all categories (shape descriptors, first and second order features).
Sphericity, spherical disproportion, information measure of correlation 2, SRE, and LRE were
within 10% difference of the average value for all cases across all phases. Normalized image
features across 10 phases for RG PET demonstrated that for all patients, 77% (7258:9464) of
image features (56 features per phase per patient) varied less than 10% from the average
values and 10.5% (998:9464) demonstrated more than 20% difference from average values
(Table 3). Features with the largest difference (>50%) were kurtosis, LGRE, SRLGE, and
LRLGE. The paired, two-tailed, t-test for RG PET inhale and RG PET exhale feature data
revealed one PET feature, namely short axis length, with p value <0.05. The CCC revealed that
the shape features had the highest CCC strength-to-agreement between image datasets from
phases 1 and phase 5 (mean CCC strength-to-agreement 0.95; moderate). First order features
and GLCM had mean strength-to-agreement values of 0.93 (moderate) and RLM features
exhibited mean CCC strength-to-agreement of 0.86 (poor).
4.3.3

Overall Feature Results

Comparisons of results among respiratory-phases and 3D-to-RG PET features, we
concluded that the features with least variability overall for PET images were sphericity,
spherical disproportion, 1st order entropy, information measure of correlation 2, and SRE.
Features demonstrating the greatest variability were kurtosis and LRLGE. For CT images,
features with the least variability were minimum intensity, mean intensity, RMS, SRE, and RPC,
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while features with the greatest variability were kurtosis, V70, V80, energy (1 st order), cluster
shade, cluster prominence, co-occurrence mean, co-occurrence variance, GLNU, and RLNU.

Figure 4.4 Feature dependency on respiration phase for selected features. (A) Normalized GLNU across
10 phases of RG PET image sets. (B) Normalized Correlation across 10 phases of a RG PET image set.

4.3.4

Long Axis Tumor Length, Rotation, and Center of Mass Motion (CMM)

The long axis tumor length and rotation results demonstrated that tumors exhibited
deformation over respiratory-gated phases. A Pearson’s correlation test demonstrated that there
was a weak correlation between the tumor angle with respect to the XY plane at inhale and the
same angle in the corresponding 3D image (R=0.350), and a weak correlation between the
tumor angle at the exhale phase and the corresponding 3D image (R=0.319). There was a weak
correlation between 3D image tumor volume and the 3D image tumor angle (R=-0.399) and
long axis length was not correlated to the breathing cycle. Table 5 shows that the long axis
length of the tumor was inconsistent across inhalation phase (phase 1), 3D scan and exhalation
phase (phase 5). The long axis lengths of the tumor for 3D, phase 1, and phase 5 were highly
correlated (3D and phase 1: R=0.936, 3D and phase 5: R=0.954, phase 1 and phase 5:
R=0.986), but long axis lengths between phase 1 and phase 5 varied indicating a possible
change in tumor shape during the respiratory cycle. The largest difference was case 11 with
long axis lengths of 124.5 mm and 139.9 mm for phase 1 and phase 5, respectively, while the
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long axis length for 3D was 147.4 mm. There was a weak to moderate correlation between
tumor angle at the inhale phase and the exhale phase (R=0.438) indicating tumor rotation
during the respiratory cycle. Moreover, the long axis angle changed from positive to negative
indicating tumor rotation. There was also a weak to moderate negative correlation between
average percent difference in 3D and RG images (in PET) and center of mass motion (R=0.445).
Table 4.5 Long Axis Lengths of Lung Tumors on 3D PET Images and RG PET Images at Exhale and
Inhale.

Case
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

4.4

Length (mm)
3D
31.58
67.19
62.73
24.67
41.00
49.21
125.95
55.03
28.11
29.05
147.42
63.53
46.96
54.12
10.94
24.59
41.55

Exhale
46.29
69.78
76.31
25.85
41.98
44.18
133.22
46.76
21.67
24.78
124.53
68.11
48.25
54.02
47.98
20.40
47.61

Inhale
35.65
66.97
71.78
24.92
40.38
43.71
126.72
46.66
21.96
21.96
139.92
63.27
55.16
54.02
47.98
19.86
39.99

Angle (relative to XY
axis)
3D
18.10
-25.98
38.72
7.62
-13.84
-36.73
-65.32
-40.82
13.45
19.74
-36.79
27.60
16.17
17.58
0.00
23.51
18.35

Exhale
-25.08
-48.58
0.00
-14.65
22.92
31.20
-68.87
-24.81
26.91
-15.30
6.03
22.59
-7.79
14.01
-15.82
-18.70
-33.33

Inhale
-39.95
-22.99
-43.10
-7.54
34.53
-8.61
-61.33
-57.25
-17.33
17.33
-37.42
14.98
-62.77
14.01
-15.82
-19.23
19.09

Volume (cc)
3D
12.57
45.77
82.56
4.69
23.47
30.41
140.78
24.84
6.45
6.85
571.04
64.35
26.21
33.25
35.40
6.75
26.01

Exhale
12.79
40.45
81.77
4.44
24.94
30.18
119.62
20.84
4.38
4.67
419.89
58.92
24.21
33.34
27.38
3.81
22.70

Inhale
12.36
40.02
77.24
4.14
21.81
29.75
113.54
19.90
4.31
4.74
427.80
53.38
28.17
32.91
30.46
2.80
22.99

CMM
(mm)
3.70
4.21
6.22
1.87
13.30
2.99
3.35
1.29
0.28
1.71
0.16
4.08
2.05
0.49
0.29
4.60
2.84

Discussion
RG PET scans can provide a “snapshot” of the tumor within a phase along the breathing

cycle, thereby greatly reducing the effects of motion on a tumor’s shape, volume, and image
feature values. In contrast, 3D PET scans convolute the absorbed activity distribution over the
motion/deformation pattern a tumor and its surroundings experience during multiple respiration
cycles (25). Consequently, a 3D (static) PET may fail to provide accurate position, volume and
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absorbed activity distribution for a mobile tumor. This is especially true in the thoracic region
and regions with substantial internal motion. This agrees with Adams’ finding that respiratory
motion affects the SUV with changes up to 30% and that any moving lesion would be
inaccurately measured due to the effects of blurring (69). In addition, patient motion/breathing is
known to cause image artifacts due to a mismatch in registration between CT attenuation
correction and emission scans (109). Internal motion, as the results support, notably affected
the image feature values of PET and CT images. The percent differences between 3D and RG
CT were generally greater than those in PET. CT images have higher spatial resolution than
PET images, and therefore more voxels for texture formation and thus a greater sensitivity to
motion. In addition, 3D CT may also be affected by motion depending on the acquisition
protocol (114).
In addition to the affine tumor motion caused by respiration, we identified deformation of
tumors (characterized by varying tumor axis lengths and angles with respect to the XY-plane
between 3D PET, RG PET at inhale, and RG PET at exhale). Conceivably, rotations and
deformations also affect image feature values. Our results demonstrated a weak correlation
between the long axis angles of RG images at inhalation and exhalation. There was also an
inconsistency of long axis length between 3D images, RG images at inhale and RG images at
exhale; thus indicating that tumor shape and rotation varied between phases. The degree to
which rotations and/or deformations affect image features, and in particular texture values,
requires further investigation.

Interestingly, there was no correlation between CMM, tumor

volume, or long axis length with 3D/RG feature value differences based on Pearson’s
correlation tests. There was, however, a weak to moderate correlation between CMM and
average percent difference.

Nonetheless, it is clear from our data that the feature value

differences between RG phases are smaller than the differences between 3D images and RG
images at a given phase. In other words, the rotational motion and/or deformation of the tumors
in our patient cohort had a smaller effect on image feature values than the averaging effects of
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the static acquisition. Yip et al. also investigated variability of texture features between 3D and
RG imaging (107). In contrast to our study, they tested only five image features (contrast,
busyness, coarseness, maximal correlation coefficient, and long run low gray). They found that
differences between 3D and RG PET were significant (107) after having accounted for noise
differences due to different acquisition times. This agrees with our findings that certain features
(e.g., kurtosis and LRLGE) demonstrated large variability between 3D and RG protocols. There
were, however, certain features in our study (e.g., SRE, 1st order entropy, and RPC) that did not
demonstrate large variability between protocols.
Figure 4.2 and Tables 4.1-4.3 show differences between feature values from 3D and RG
protocols. The features with the smallest change across PET for all RG bins and for 3D PET
were sphericity, spherical disproportion, entropy (1st and 2nd order), sum entropy, information
measure of correlation 2, SRE, LRE, and RPC. Interestingly, a study by Galavis et al. on the
variability of PET texture features caused by different acquisition modes and reconstruction
parameters demonstrated that 1st order entropy exhibited small variation (≤ 5%) while 2nd order
entropy, and sum entropy exhibited intermediate variability (10%-25%) (45). Our results were
comparable, showing that 1st order entropy exhibited variation smaller than 5% and that 2nd
order entropy and sum entropy exhibited less than 10% difference between 3D and RG PET
protocols. Sum entropy, 2nd order entropy, and the information measure of correlation 2 are
based on entropy calculations which measure randomness in a pattern.

A portion of the

randomness can be attributed to the noise intrinsic to the scanner while the remaining can be
attributed to statistical differences in counts (quantum noise). Hence 3D images are less noisy
than RG images since percentage image noise is given by (1⁄√N) ∙ 100, where N is the count
density (counts/cm2). Thus, 3D/RG feature differences are a combination of both tumor motion
and count statistics. This suggests that it would be informative to normalize for count density.
Unfortunately, this study was retrospective and list-mode data were not accessible for
normalization. Nevertheless, the number of counts and therefore the noise among RG images
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from the 10 phases can be assumed similar. Therefore, the differences in feature values from
phase to phase may be attributed to the effect of motion and/or deformation.
The features LRE, SRE, and RPC, which demonstrated small change across PET for all
RG bins and 3D PET are features from the run length matrix. LRE measures the long run
emphasis distribution. Correspondingly, SRE measures the short run emphasis distribution. Run
percentage is the ratio of the number of runs to the number of pixels in an image (Table 4.5).
We conclude that the cumulative number and length of short runs and cumulative number and
length of long runs does not vary significantly between 3D and RG images, and that the total
number of runs does not vary significantly between 3D and RG images. These conclusions
may depend on the algorithms used to calculate these features. For example, in this paper we
averaged runs from 13 directions; other definitions are possible.
Feature differences between 3D and RG in PET and CT images that showed large
differences (>50%) were typically features from intensity volume histograms such as kurtosis
and TGV. Thus, the intensity histogram distributions between 3D and RG features were quite
different in terms of symmetry about their means and the degrees of “peakness” of their
distributions. Cluster shade and cluster prominence exhibited large differences in CT. These
features measure the skewness of the GLCM (93). According to Ion, a high cluster shade value
reveals an asymmetric image (93).
Overall, it is clear that image feature values are different between 3D and RG images.
As discussed above this is due to both the smearing effects of tumor motion, both affine and
non-affine, and noise intrinsic to image acquisition—the former apparently having larger effect
(107). This is also supported by the relative variation in feature values from different phases of
the RG scans even though the tumor VOIs varied from phase to phase due to motion and
deformation. Thus, the motion convoluted into the 3D images seems to have a greater effect on
feature values than noise, given that the RG images are intrinsically noisier due to lower counts
(acquisition times). This study suggests that it would be important to account for motion in
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quantitative image feature analysis, regardless of modality (PET or CT), as attempted by other
investigators (38). Alternatively, if the definition of any one feature includes details of the
acquisition protocol, then 3D and RG features may be treated as “different” sets of features.
Further studies are needed to elucidate the potential usefulness of this alternative definition.
4.4.1

Limitations

Though our results clearly demonstrated that image feature values were different
between 3D and RG protocols, there were limitations to the study. First of all, we were unable to
normalize for count density between 3D and RG protocols. Another limitation was the
nonconformity of the uptake time with the protocol. This was mainly due to clinical logistics.
Also, partial volume effects were not taken into account. Since 3D and respiratory-gated data on
same patient were acquired on the same scanner, and hence partial volume effects were similar
in both sets of images except for the effect of motion, we did not take these affects into account.
In addition, binning artifacts and breathing irregularities were assumed negligible since only
patients with regular breathing patterns are candidates for RG PET for radiotherapy in our
institution (115). Another limitation was that 4D PET received 3D CT attenuation correction. This
is currently standard procedure at our institution. Lastly, our patient size was limited, but
comparable to other published studies (37, 38, 107). We plan to address these limitations in
future studies.
4.5

Conclusions
This study investigated the variation of image features between 3D and respiratory-

gated PET/CT images of lung tumors. To our knowledge, this is the first study that evaluates
how 3D and RG acquisitions affect a large number of image features currently being used and
tested in several medical applications. The data showed that image feature analysis using a
static acquisition (3D) versus a respiratory-gated acquisition (to account for motion of the ROI)
revealed notably different feature values. The results support that these differences are mainly
due to the effect that respiratory motion has on image features. We have also concluded that
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rotational motion and deformation of the tumor also affect the features of an image. However,
the effect of rotational motion and deformation from phase to phase appear to be smaller than
the averaging/smearing effects of static acquisition. In sum, this study calls attention to the
differences in 3D and RG image feature values for mobile tumors.

The predictive and/or

prognostic power of RG versus 3D image feature values will be explored in future studies.
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Chapter Five: Sensitivity of Image Features to Noise in Conventional and RespiratoryGated PET/CT Images of Lung Cancer: Uncorrelated Noise Effects5
5.1

Introduction
Clinical imaging by Positron Emission Tomography (PET) and Computed Tomography

(CT) is evolving into a quantitative discipline where a large number of metrics are computed in
the intensity and gray-level matrix domains; this discipline has been termed Radiomics (36, 42).
Radiomics of CT & PET images have shown promise as a diagnostic, prognostic, and predictive
tool in cancer treatment (13, 33, 36, 40, 116). It is also being combined with other “omics” (e.g.,
genomics, transcriptomics, proteomics, metabolomics) into decision support systems (84).
However, features are sensitive to various acquisition conditions (scanner type, image
reconstruction algorithm, etc.) (13, 33, 36, 40, 45, 116). One major confounding factor
introduced by these conditions is the presence of various random contributions to the signal,
commonly referred to as noise. However, few authors have examined the impact that quantum
or electronic noise can have on Radiomic features. In this paper, we examine the influence of
electronic noise, a signal independent contributor to image noise, on Radiomics.
An image feature is a quantity that provides quantitative information about an image. It
can be derived directly from the image (1st order), or from heterogeneity matrices that are
derived from the image (2nd order). Image features or “metrics” that describe image texture and
heterogeneity analyze relationships between voxel pairs or groups of voxels. When noise is
introduced into an image the fundamental relationships between voxels are altered. As a result,
the image metrics are also altered and the texture or heterogeneity of the object may be
misrepresented. If not accounted for, this noise can have significant implications on the clinical
utility of image features. Although there are protocols for the standardization of PET/CT
5

Portions of this chapter have been submitted for publication.
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imaging, image noise varies between scanners, manufacturers, and institutions (109, 117, 118).
Thus, the impact of noise on image features may adversely affect multi-institutional studies
involving radiomics.
Although the focus of this study is on image noise, motion is also a factor that affects
image quality. It can affect SUV by up to 30% and causes image artifacts because of
registration mismatches in the attenuation correction (CT) and emission scans (69, 109). In
PET, respiratory-gated (RG or 4D) images tend to have higher levels of noise because of the
smaller number of counts (due to shorter acquisition times per bed position), but the quality of
RG images are impacted less by motion. Both conventional (3D) and respiratory-gated (4D)
images are included in this study.
Since the goal of Radiomics is the clinical application of image features, it is important to
carefully characterize image features and to understand how they might be influenced by
various clinical situations with varying levels of noise. The goal of this study is to evaluate the
effects of noise on image features.
5.2

Materials and Methods
5.2.1

Phantom Study

A standard ACR accreditation phantom with a Germanium (Ge)-68 cylindrical insert
(Benchmark by RadQual LLC, Weare, NH, SN: BMCY06813067103), was placed on a motion
table with 2.4 cm motion amplitude and a 4 second period to simulate lung tumor motion due to
the respiratory cycle. The phantom was imaged with three protocols: 1) 3D PET/CT with motion,
2) 4D PET/CT with RG motion, and 3) 3D PET/CT without motion (static).
5.2.1.1 Noise Application
To assess the implications of electronic noise on image features, uncorrelated Gaussian
noise with varying standard deviations was added to PET and CT patient and phantom images.
A custom program was used to apply noise with varying standard deviation to phantom images
using the following Gaussian function (pg, Equation 5.1).
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[ 𝑝𝑔 (𝑧) =

(𝑧−𝜇)2

1
−
𝑒 2𝜎2
𝜎 √2𝜋

]

(5.1)

where μ is mean noise added, σ is standard deviation, and z is gray level. CT noise images
were created with standard deviations of 10, 20, 50, 80, and 120 Hounsfield Units (HU). These
will be referred to as GN10, GN20, GN50, GN80, and GN120 henceforth. PET noise images
were created with standard deviations of 2.5%, 4.0% and 6.0% of the maximum intensity (not
SUV). These will be referred to as low noise, medium noise, and high noise. PET images had
varying standard deviations due to the variation in maximum intensities (not an issue in
phantoms but very significant in patient images). Although the GN120 noise level may represent
greater levels of electronic noise than expected in a scanner, we believe this was necessary to
clearly distinguish noise-affected features. The low noise levels of GN10 and GN20 were
included to demonstrate how small noise levels affect image feature analysis. The higher noise
levels were included to show the gross effects of noise on feature analysis. As demonstrated by
Latifi et al., low-dose 4D CT settings sometimes involve high levels of noise (119).
The specific activity (SA) of the ACR phantom was calculated using the activity on the
date of source production (108274.4 Bq/cm3 on 03/20/2013), the date of measurement
(02/18/2014), and the volume of the source (58.1 cm3). The measured specific activity was
calculated using Mirada DBx (Mirada RTx, Mirada Medical, Oxford, UK). Mean counts (105527
Bq/cm3) and standard deviation (2927.7 Bq/cm3) were obtained from the cylindrical ROI (24.4
cm3) inside the volume-of-interest (VOI). The reciprocal of the coefficient of variation, or SNR,
which was 2.7% from the noise contribution in the phantom data, was calculated.
5.2.1.2 Signal-to-Noise Ratio (SNR) and Noise Power Spectrum (NPS)
To understand the noise inherent in the images and to quantify the noise added to the
images, the signal-to-noise ratio and noise power spectrum of the scanner was calculated. The
noise power spectrum (NPS), representative of the noise texture of an image (used primarily in
CT modalities) was calculated using the Ge-68 phantom. The signal-to-noise ratio (SNR),

64

representative of the amplitude of noise in an image was also calculated on the phantom for
both PET and CT modalities to verify and quantify the addition of noise to the images.
The SNR of a GE Discovery STE PET/CT Scanner was measured with the Ge-68
phantom with activities of 0.62 mCi and 0.79 mCi. The phantom was scanned with 70 cm fieldof-view (FOV), 120 kV, 210 mA, 28 subsets, 2 iterations, and FWHM of 7 mm for 3D PET/CT
and 60 cm FOV, 120 kV, 200 mA, 28 subsets, 2 iterations, and FWHM of 7mm for 4D PET/CT.
To calculate the CT SNR, medical imaging software (Mirada RTx, Mirada Medical, Oxford, UK)
was used to draw five 4 cm spheres onto the phantom image (figure 5.1a). For PET SNR, two 4
cm spheres were drawn on the phantom image. One sphere was inside the Ge-68 source and
the other was in a non-radioactive region inside the phantom (figure 5.1b). The SNR was
calculated using Equations 5.2-5.4:
𝑠𝑖𝑔𝑛𝑎𝑙 → [ 𝑠 = ∑𝑛𝑖=1 ̅̅̅̅̅
𝐻𝑈𝑖 ]

(5.2)

𝑛𝑜𝑖𝑠𝑒 → [ 𝜎̅ = √∑𝑛𝑖=1 𝜎𝑖2 ]

(5.3)

𝑠

𝑆𝑁𝑅 → [ 𝑆𝑁𝑅 = 𝜎̅ ]

(5.4)

where s is the signal, ̅̅̅̅̅
𝐻𝑈𝑖 is the mean HU for region i; n is the number of regions and 𝜎̅ is the
mean standard deviation across all VOIs;

i

is the standard deviation for region i.

A CT image of the Ge-68 phantom was used to calculate the NPS of the GE PET/CT
Scanner at our institution. Ten axial slices; four regions per slice were selected in the uniform
region of the phantom. A gain correction was applied by subtracting the mean value of the
regions and the Fourier transform was applied to each region to create a two-dimensional noise
power spectrum. Forthwith, a one-dimensional NPS was plotted from the two-dimensional noise
power data (figure 5.2) by radial averaging.
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Figure 5.1 Method of SNR Calculation for (a) CT and (b) PET using Ge-68 solid epoxy phantom.

Figure 5.2 Method to measure CT noise power spectrum using Ge-68 solid epoxy phantom: 1) Gather 4D
independent images. 2) Apply gain & offset correction and subtract mean. 4a) Take 2D Fourier Transform
of each image. Take magnitude of results & square it. Calculate Average of 40 results. 5) Calculate 1D
NPS by radial average of the 2D result.

66

5.2.2

Patient Study
Twenty-six non-small cell lung cancer (NSCLC) patients with 3D and RG PET/CT

images were retrospectively selected for this study with ages from 47 to 83 years, eleven males
and fifteen females. This study was approved with waived informed consent by the University of
South Florida Institutional Review Board #105996.

Standard of practice procedures at our

institution were followed. Gaussian noise was applied to all 3D and one RG phase of PET and
CT patient images according to the method described previously (equation 1). Resulting PET
and CT datasets consisted of four separate image sets for each patient, an original image
dataset and image datasets of low, medium, and high noise for 3D PET, 4D PET, 3D CT and
4D CT. Figure 5.3 demonstrates the noise levels for PET and CT for one case (coronal view).

Figure 5.3 One coronal slice of a PET/CT image with and without noise. (A) Original image. (B) CT image
with Gaussian noise (σ =120 HU). (C) PET image without noise. (D) PET image with Gaussian noise (σ
=0.06*maximum intensity).
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5.2.2.1 Feature Extraction
The original and noise-added image sets were imported, viewed, and contoured with
Mirada Medical Software (RTx, Mirada Medical, Oxford, UK). Lung tumor contours were
acquired separately for noise and original images. PET image tumors were contoured at 40%
maximum intensity inside a defined volume of interest. On CT images, tumors were contoured
with CT region segmentation. An in-house program extracted image features for the region
represented inside each contour. Eighty-one image features were extracted: 11 shape features,
22 intensity features, 26 Gray Level Co-occurrence Matrix (GLCM) features, 11 Run Length
Matrix (RLM) features and 11 Gray Level Size Zone Matrix (GLSZM) features (29, 63, 64, 111)
(see Table 2.1 for a complete list.) The dimension of the co-occurrence matrices were 128x128,
calculated based on the 3D images with a step size of 1 voxel in 13 directions. The gray levels
were binned into 128 levels with equal intensity intervals for the run-length matrices. The run
length was calculated with the 3D images in 13 directions. These 13 directions are defined by
Xu et. al (110, 112).
5.2.2.2 Statistical Analysis on Patient Data
Conventional and 4D PET and CT image feature differences were evaluated separately
resulting in four datasets: 3D PET, 3D CT, 4D PET, and 4D CT. Features from original images
were compared to image sets with varying Gaussian noise levels for each case. Percent
difference (Equation 5.5) was used to compare image features extracted from noise images
(low, medium, and high noise) and original images.
[ %𝐷𝑖𝑓𝑓𝑖𝑗𝑛𝑜𝑖𝑠𝑒 = 100 × |

𝑁𝑉𝑖𝑗 −𝑂𝑉𝑖𝑗
𝑂𝑉𝑖

|]

(5.5)

where NVij is the value of feature j at noise level i and OV j is the value of feature j from the
original image. The percent differences were averaged for each level of noise across all
patients. Features varying on average by more than 100% were considered “non-robust” (those
features that are not reliable or reproducible across noise). Those varying less than 10% were
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considered “robust”. Features were classified into one of 11 categories for CT: R1, R2, R3, R4,
R5, NR1, NR2, NR3, NR4, NR5, and B; and 7 categories for PET: R1, R2, R3, NR1, NR2, NR3,
and B. These are defined in Table 5.1.
Table 5.1 CT and PET Feature Classifications.

Feature Classifications
R1
R2
R3

%𝐷𝑖𝑓𝑓 < 10% for CT noise level GN120 and PET highest noise level;
Robust1
%𝐷𝑖𝑓𝑓 < 10% for CT noise level GN80 and PET mid noise level;
Robust2
%𝐷𝑖𝑓𝑓 < 10% for CT noise level GN50 and PET lowest noise level;
Robust3

R4

%𝐷𝑖𝑓𝑓 < 10% for CT noise level GN20; Robust4

R5

%𝐷𝑖𝑓𝑓 < 10% for CT noise level GN10; Robust5

NR1
NR2
NR3

%𝐷𝑖𝑓𝑓 > 100% for CT noise level GN10 and PET lowest noise level;
Non-robust1
%𝐷𝑖𝑓𝑓 > 100% for CT noise level GN20 and PET mid noise level; Nonrobust2
%𝐷𝑖𝑓𝑓 > 100% for CT noise level GN50 and PET highest noise level;
Non-robust3

NR4

%𝐷𝑖𝑓𝑓 > 100% for CT noise level GN80; Non-robust4

NR5

%𝐷𝑖𝑓𝑓 > 100% for CT noise level GN120; Non-robust5

B

10% < %𝐷𝑖𝑓𝑓 < 100% for CT noise level GN10 and PET lowest noise
level

In addition to percent difference, the concordance correlation coefficient (CCC) was
calculated for each feature between different levels of noise and the original image to assess
whether feature values were consistent for different noise values. The strength of agreement
classification is demonstrated in Table 5.2 (113).The mean CCC for each feature subtype was
calculated and the median and range for each feature across noise levels were plotted.
Table 5.2 CCC Strength of Agreement Scale.
Strength of Agreement CCC Score
High
>0.99
Substantial
0.95-0.99
Moderate
0.90-0.95
Poor
<0.90
*This scale originated from McBride (113).
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5.3

Results
5.3.1

Phantom Study

The SNR for PET and CT images behaved as expected by decreasing as noise level
increased (Figure 5.4) indicating that uncorrelated Gaussian noise increased the image noise.
The measured NPS (Figure 5.5) showed the noise texture associated with the scanner at our
institution (using the phantom CT image). The NPS for the original CT image was spatial
frequency dependent, indicating correlated noise texture (Figure 5.5a). Whereas, the noise
power spectra of the CT images with high levels of added noise were spatial frequency
independent indicating that the addition of Gaussian noise overwhelmed the correlated noise
inherent to the image generation process (Figures 5.5d, 5.5e, 5.5f). The noise power spectra of
the low noise level images, GN10 and GN20 (Figures 5.5b, 5.5c) were not completely spatial
frequency independent demonstrating that the inherent scanner noise power was still
represented in part at these levels.
5.3.2

Patient Study

The automatic contouring via intensity threshold in the lung was not significantly affected
by the noise. The R1 (%𝐷𝑖𝑓𝑓 < 10% for highest added noise, Table 5.3) features with (%𝐷𝑖𝑓𝑓 <
2%) for 3D CT were minimum intensity (<2%), peak intensity (<2%), mean intensity (<1%), rootmean-square (<2%, RMS), I30 (<1%, intensity ranging from lowest to 30% highest intensity
volume), 1st order entropy (<1%) and inverse difference moment (<2%). The results were
comparable for 4D CT (see Table 5.3). In addition to the 3D CT R1 features, the 4D CT R1
features included short axis, eccentricity, max intensity, V10-V90 (percentage volume with at
least 10% intensity minus percentage volume with at least 90% intensity), and histogram
entropy. However, the 4D R1 features did not include 1st order contrast and local homogeneity.
Minimum intensity, peak intensity, mean intensity, RMS, I30, 1st order entropy, and inverse
difference moment exhibited differences less than 1% for 4D CT. No features from the GLSZM
were categorized as R1 features from 3D or 4D CT.
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Non-robust features were defined as features that exhibited %𝐷𝑖𝑓𝑓 > 100% for the
lowest level of added noise (NR1, Table 5.4). The 3D CT NR1 features included V70 (113%,
percentage volume with at least 70% intensity) and V80 (278%, percentage volume with at least
80% intensity) from intensity features, as well as large-area emphasis (LAE, 105%), lowintensity emphasis (LIE, 375%), low-intensity large-area emphasis (LILAE, 410%), high-intensity
large-area emphasis (HILAE, 184%), and intensity variability (IV, 135%) from the GLSZM. The
CT NR1 features for 4D CT included V40 (138%, percentage volume with at least 40% intensity)
and variance (182%) from the intensity features and SAE (121%, small-area emphasis), LIE
(115%), LISAE (159%, low-intensity small-area emphasis), HISAE (245%, high-intensity smallarea emphasis), LILAE (136%), and HILAE (930%) from the GLSZM.
For PET (3D and RG), shape features that depended solely on automatically drawn
contours were the most stable. R1 features exhibiting %𝐷𝑖𝑓𝑓 < 2%included: surface/volume,
sphericity, spherical disproportion, mean intensity, RMS, I30, 1st order entropy, 1st order local
homogeneity, histogram entropy, entropy (<2%), inverse difference moment (<1%), inverse
difference (<1%), sum average, sum entropy (<2%), information measure of correlation 2
(<2%), SRE (<0.5%). There was one GLSZM R1 feature: zone percentage (ZP). In 4D PET, the
R1 shape and intensity features were the same as 3D PET, excluding contrast (1 st order).
GLCM R1 features were the same as R1 features. Entropy, inverse difference moment (<1%),
inverse difference (<1%), sum entropy, and information measure of

correlation 2

exhibited %𝐷𝑖𝑓𝑓 < 2%. RLM R1 features included SRE (<0.5%), LRE, high gray-level run
emphasis (HGRE), short run high gray-level emphasis (SRHGE), long run high gray-level
emphasis (LRHGE), gray-level non-uniformity (GLNU), RLNU, and RPC. The GLSZM R1
feature was ZP (the same as in 3D PET).
The non-robust features from the lowest level of noise (NR1) from 3D PET included
LGRE (167%), short run low gray-level emphasis (SRLGE, 168%), and long run low gray-level
emphasis (LRLGE, 164%) from the RLM and LIE (275%), LISAE (253%), LILAE (1437%) from
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the GLSZM. There were fewer NR1 features from 4D PET. These features were from the
GLSZM and included LIE (541%), LISAE (701%), and LILAE (610%).

Figure 5.4 Signal to noise ratios for: (A) 3D and 4D CT (one phase) of phantom with motion table and
static (3D only). (B) 3D and 4D PET phantom with motion table and static (3D only).

Figure 5.6 shows the trend between average percent differences for feature subgroups.
For PET, shape, intensity, and GLCM features demonstrate an increase in difference with
added noise. In CT this trend applied only to GLCM and GLSZM features, only with 3D CT.
However, in both PET and CT, shape features exhibit the least change with uncorrelated noise
(<4% average difference in PET and <11% average difference CT) and GLSZM features were
the most sensitive to uncorrelated noise.
The CCC values further demonstrated that feature subtypes responded differently to
added noise. GLSZM features demonstrated average CCCs below 0.90 for all modalities and all
levels of noise (<0.70 for PET and <0.62 for CT). This demonstrated a poor agreement between
the image features from noise and original images for GLSZM and supports our percent
difference results. There was a discrepancy between PET and CT with the RLM CCC scores. In
PET (3D and 4D), the RLM features demonstrated the highest CCC values across noise levels,
followed by the shape descriptors, first order features, GLCM, and GLSZM (except for the
medium level of noise where GLCM has a higher average CCC than first order features).
Although the feature subtypes had an order, the distinction was not pronounced. Besides the
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GLSZM features, all other average CCCs were greater than 0.95 and thus there was a
substantial strength-to-agreement between these features derived from noise images and
original images for feature subtypes excluding GLSZM.
In CT, the average CCCs were highest for shape descriptors, followed by the first-order
features, GLCM, RLM, and GLSZM. Unlike PET, there was a clear distinction between the CCC
values for different feature subtypes. Figures 5.7 and 5.8 demonstrate the median CCCs for
each feature across noise with the ranges (min to max) for 3D CT, 4D CT, 3D PET, and 4D
PET.

Figure 5.5 NPS of Ge-68 solid epoxy phantom for GE Discovery STE PET/CT scanner with increasing
image noise. (A) Original NPS of CT image of phantom. (B NPS of CT image with added Gaussian noise
(σ=10 HU). (C) NPS of CT image with added Gaussian noise (σ=20 HU). (D) NPS of CT image with
added Gaussian noise (σ=50 HU). (E) NPS of CT image with added Gaussian noise (σ=80 HU). (F) NPS
of CT image with added Gaussian noise (σ=120 HU). Note: Y-scale changes from (A) to (F).
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Table 5.3 R1 Features (%𝑫𝒊𝒇𝒇 < 𝟏𝟎%) for CT and PET.
Subtype

Feature
3D CT
4D CT
3D PET
4D PET




Volume




Surface Area




Surface Area/Volume




Sphericity




Compactness
SHAPE




Spherical Disproportion




Long Axis



Short Axis



Eccentricity




Convexity




Minimum Intensity




Maximum Intensity




Peak Intensity




Mean Intensity


Standard Deviation


Skewness


Coefficient of Variation




TGV




RMS
INTENSITY




I30


I10-I90



V10-V90




1st Order Energy




1st Order Entropy



1st Order Contrast



1st Order Local Homogeneity




Histogram Entropy


Uniformity


Homogeneity


2nd Order Entropy


Dissimilarity




Co-occurrence Mean




Inverse Difference Moment




Inverse Difference


Sum Average
GLCM


Sum Entropy


Difference Average


Difference Variance


Difference Entropy


Info Correlation 1


Info Correlation 2




SRE


LRE

HGRE

SRHGE
RLM

LRHGE

GLNU


RLNU




RPC


ZP
GLSZM
Abbreviations: GLCM = gray-level co-occurrence matrix; RLM = run length matrix; GLSZM = gray-level size zone matrix
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Table 5.4 NR1 Features (%𝑫𝒊𝒇𝒇 > 𝟏𝟎𝟎%) for PET and CT.
Subtype
INTENSITY
GLCM
RLM

GLSZM

Feature
V40
V70
V80
Co-occurrence Variance
LGRE
SRLGE
LRLGE
SAE
LAE
LIE
LISAE
HISAE
LILAE
HILAE
IV

3D CT



4D CT



3D PET

4D PET





























Abbreviations: GLCM = gray-level co-occurrence matrix; RLM = run length matrix; GLSZM = gray-level size zone matrix

Figure 5.6 Average percent differences between noise and original images across feature sub-types for
low, medium, and high noise in (A) 3D CT, (B) 4D CT, (C) 3D PET, and (D) 4D PET.
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Figure 5.7 Median CCCs for all CT features – (A) 3D CT and (B) 4D CT – for the levels of noise including
GN10, GN20, GN50, GN80, and GN120 range.

5.4 Discussion
We applied uncorrelated noise to phantom and patient images to analyze its effect on
image features. We found that uncorrelated noise effects in GLCM, RLM, and GLSZM features
were generally greater than those seen in shape features. Given what these texture features
seek to measure, this finding is not surprising.

Since GLCM, RLM, and GLSZM features

measure the relationships between pixels and the addition of noise (correlated or uncorrelated)
alters these relationships, these texture features would be affected more than shape features
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which depend mainly on the contour defining the tumor volume (VOI). Specifically, the GLCM
measures spatial relationships between pixel pairs and the RLM measures runs of the same
gray level across an image. GLSZM, introduced by Thibault et al., is an advanced statistical
matrix that measures homogeneity (41, 63). All matrices, except the GLSZM, were calculated
along multiple directions. Shape features however, are based on the size, shape, and convexity
of VOI’s contour, which were essentially not affected by the addition of uncorrelated noise.

Figure 5.8 Median CCCs for all PET features – (A) 3D PET and (B) 4D PET – for the levels of noise
including low, medium, and high levels of noise.
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Adding uncorrelated noise to PET images with large areas of uptake in the tumor, brain
or bladder resulted in less significant affect from added noise. The large areas of high uptake
created a bigger dynamic window of intensities and thus the added noise appeared to be less
significant. For this reason, in situations where there are large tumors with high uptake, the
uncorrelated image noise may not be a significant problem in feature analysis.
We discovered that the effects of Gaussian added noise in CT were usually smaller in
4D images than 3D images. We believe that since the original image noise of 4D images was
greater than 3D images, the difference between original image features and noise image
features was not as prominent. This also affected the CT SNR. The visible trend for PET
wherein feature differences increased as noise increased was less distinguishable in CT;
especially in 4D CT (Figure 5.6). The added noise appears to have altered the CT SNR to a
greater degree than PET SNR (see Figures 5.4a and 5.4b). It is clear that at higher noise levels,
beginning at the GN50 noise level, the CT SNR converges implying that the Gaussian noise
destroys the differences in SNR due to acquisition. Figure 5.4 demonstrates that at the GN50
noise level, the SNR for 4D CT had decreased by a factor of two. At the GN120 noise level, the
SNR for CT decreased nearly 5 times compared to PET where the SNR decreased by a factor
of one.
It is interesting that the SNR for 3D PET is lower than that of 4D PET especially when
compared with the CT SNR. This could be due to motion effects. 4D PET accounts for motion.
Since PET images are acquired over a rather long period of time (4 minutes per bed position),
when motion is introduced into an image and not accounted for (as in 3D images) an averaging
effect is introduced into the image and the true tumor location, size and shape is warped. We
believe this is why the static PET image and 4D motion images have similar SNRs and 3D
motion exhibits the lowest SNR. The SNR results in CT were drastically different from PET. To
start, 3D motion had the highest SNR followed by static and finally 4D motion. Since CT images
are acquired much faster than PET images, on the order of milliseconds and are much less
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sensitive to motion, it makes sense that the static and 3D motion images had the highest SNRs;
they received a higher number of counts than 4D CT. It is also interesting that the PET SNR is
considerably lower (40x for 3D motion) than the CT SNR even for the original images.
In PET images, the 3D and 4D image feature differences were comparable. Although
there were fewer features in the NR1 category for 4D PET, differences were not consistently
larger for 3D or 4D PET across all feature subtypes. In addition, the percent difference in PET
features did not always increase with respect to added noise. For instance, in the RLM and
GLSZM features, average differences reached the maximum (4D PET) or minimum (3D PET)
percent difference at the medium noise level (Figure 5.6). This could be caused by the large
pixel size in PET, the high level of noise in the image due to decreased counts, or simply a
saturation of the uncorrelated noise in the image at the low or medium noise levels. Figure 5.4
demonstrates that the PET SNR did not decrease sharply for 3D Motion, 4D Motion, or 3D
Static PET indicating high levels of initial image noise.
The finding that shape descriptors were less affected by noise than GLCM, RLM, and
GLSZM features is favorable for the field of radiation therapy. Increasingly common, the gross
tumor volume (GTV) for radiation treatment planning is contoured using both PET and CT. The
addition of PET as a diagnostic tool in radiation therapy has improved GTV definition and
demonstrated a 21-100% change in tumor volumes (120). PET in radiation treatment planning
improves the contouring accuracy of the GTV which promotes decreased toxicity to healthy
tissue (105, 121).
The large differences in intensity, GLCM, RLM, and GLSZM features demonstrate that
uncorrelated image noise affects image feature analysis. GLSZM features are highly unstable,
particularly in 3D CT, with average values nearing 100,000% in some cases but as low as 0.4%
in others. The full extent of this effect requires further investigation but it is clear that image
features, especially those from intensity, GLCM, RLM, and GLSZM are affected by uncorrelated
noise. Investigators that are using large numbers of images from multiple scanners should be
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aware of the effects of image noise on image feature analysis. This was recently illustrated
nicely for correlated noise by the work of Nyflot et al. (48). Although we did not compare results
from multiple scanners, quantitative accuracy in PET/CT is still being established (48). Multicenter PET/CT trials testing the stability and repeatability of PET data from different sites
demonstrated that the quantitative PET measurement, standardized uptake values (SUV), were
within the PET Response Criteria in Solid Tumors (RECIST) limitations, but were higher than in
a previous study conducted in smaller single-center studies (48). Even inside a single institution,
patients imaged on the same scanner demonstrated SUV differences approaching 50% on test
and retest analysis (2). It is clear that studies involving multiple scanners should be aware of the
effects of image noise on their features.
The noise texture, defined by the measured NPS was uniform in shape for the highest
levels of added noise demonstrating that we had indeed added uncorrelated noise to the
images. This uncorrelated noise is commonly termed “white noise” and in this study is
considered random noise of a Gaussian distribution. A distinct difference existed between noise
phantom NPS and original phantom NPS due to the shift from the inherent correlated noise in
the image to uncorrelated Gaussian noise.
Uncorrelated noise is not the only criteria that affect PET/CT image features. Nyflot et al.
tested the effect of correlated (stochastic) noise on image features, as well as patient size,
lesion size and image reconstruction method. They determined how stochastic noise have
various effects on different feature subtypes – what they term “classes of metrics” - concluding
that additional standards are warranted for prospective PET image feature analysis studies
towards predicting clinical outcome or treatment response (48). Other studies have shown that
motion, bin width, and SUV discretization, acquisition modes and reconstruction parameters
also affect image features and in some cases the extent of these effects are feature dependent
(45, 47, 48, 122). A common conclusion of these studies was that standardization of image
feature analysis in Radiomics is needed. We join in agreement with these studies that
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standardization is crucial as we look towards the application of Radiomics in Radiotherapy and
other fields. We are also advocating for standardization of image feature analysis, especially in
PET/CT, to promote accuracy and patient safety (if features are applied prospectively) when
measuring image features for clinical purposes and to encourage accurate image feature study
comparisons between scanners, institutions, and manufacturers.
There were limitations to this study. The major limitation of this study was that we did not
have access to the pre-reconstruction PET/CT data due to proprietary reasons. This was a
retrospective study; however, we wanted to determine the effect of noise on archived patient
studies. These limitations affected the approach in which noise was added to the PET/CT
images as typically done (48, 123). In typical imaging systems PET and CT image noise is
integrated into the reconstruction method and not necessarily additive, except in the case of
electronic noise. Nevertheless, our method still allowed us to measure the sensitivity and
degradation of Radiomic features due to noise.
5.5

Conclusions
Uncorrelated noise was added to PET and CT images. Shape, intensity, GLCM, RLM,

and GLSZM image features were extracted from VOIs and image features that were non-robust
with respect to the additional noise were identified. Many intensity, GLCM, RLM, and GLSZM
features varied significantly with noise. Percent change between original and noise image
features increased as noise level increased for intensity and GLCM features in PET, and GLCM,
RLM, and GLSZM features in CT. GLSZM features were the most sensitive to noise both for CT
and PET. A good understanding of features sensitivity to noise is essential for image features
analysis and Radiomics studies involving a large number of images from multiple scanners as
would be the case in multi-institutional clinical trials. This study adds support to the proposal for
standardization of clinical processes and analysis involved in Radiomics.
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Chapter Six: Fiducials vs. 18F FDG PET/CT for Esophageal Cancer GTV Delineation for
Radiotherapy Treatment Planning6
6.1 Introduction
The five year survival rate for esophageal cancer patients is 18% and there are
approximately 17,000 estimated new esophageal cancer cases and nearly 16,000 estimated
deaths for 2016 (124). This is perpetuated because most esophageal patients present with
locally advanced or metastatic disease (54). To improve outcomes, neoadjuvant therapy is
recommended for patients with locally advanced disease prior to surgery (125). At present, data
on individual sensitivity to chemotherapy and radiation therapy is lacking, thus patients are
advised to undergo standard of care chemoradiation based on their clinical, rather than
molecular, factors. Clinicians rely on radiographic indicators to assess response but, in the
absence of progression at restaging, patients proceed to esophageal resection; the quality of life
implications and medical cost of this are profound if patients have a pathologic complete
response and yet have undergone removal of their esophagus. Conversely, if patients are found
at the time of surgery to have had no response, their outcomes are no better than if they went
directly to surgery upfront (57). In fact, in the case of the pathologic non-responder, there is
also the consideration of the potential acute neoadjuvant toxicity incurred for no demonstrable
benefit at a delay of at least 12 weeks from diagnosis until definitive surgery.
3D

18

F-Fluorodeoxyglucose (FDG) PET/CT is obtained routinely for the initial staging of

esophageal cancer and has been shown in several sites to alter the GTV delineation (126-129).
Specifically in the esophagus, 3D PET/CT has been shown to improve staging (130).
Theoretically, PET/CT could eliminate the need for additional staging methods in patients with
distant metastatic disease (125). This would expedite treatment and avoid potentially ineffective
6

Portions of this chapter have been submitted for publication.
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treatment methods. Not only does 3D PET/CT identify the primary tumor location, it is an early
assessment tool for treatment response, outcome prediction and therapy modification (131133).

FDG PET is able to detect most primary tumors and lymph nodes. Studies have

demonstrated a sensitivity of 30-93% and a specificity of 79-100% for lymph node detection
(134).
Endoscopically-placed fiducial markers have facilitated determination of respiratory
associated tumor motion in the treatment of esophageal cancer as well as strategies of
abdominal compression to decrease such motion, which has enhanced a conformal approach,
particularly when used in conjunction with image-guided radiation therapy (IGRT) (135). It is
common, when planning esophageal cancer radiotherapy treatment, that accounting for
microscopic disease, nodal involvement, and tumor motion is associated with larger planning
target volumes (PTV) and consequently, increased concern about the amount of normal tissue
irradiated (136). Studies have shown that increased areas of irradiated tissues can result in
harmful effects such as radiation pneumonitis, pericardial effusion, and pleural effusion (136). At
our institution, all trimdodality esophageal cancer patients receive 3D PET/CT imaging prior to
treatment. In a study on 81 esophageal patients, respiratory associated superior-inferior tumor
movement of 1.25 cm for proximal and middle esophageal tumors and 1.75 cm for those in the
distal esophagus were noted (136).
The role of 3D PET/CT in esophageal tumors that move with respiration and have the
potential for significant mucosal inflammation is unclear. The GI research group at Moffitt
Cancer Center previously reported the stability data of esophageal fiducial markers
endoscopically implanted under ultrasound guidance within 1 cm from the superior and inferior
edges of the tumor (135). However, the correlation between gross tumor volumes derived from
3D PET/CT vs. endoscopically placed fiducial markers has not yet been reported. This work
tested the correlation between metabolic tumor volumes (MTV) derived from 3D PET/CT and
endoscopically placed fiducial markers using ultrasonography.
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6.2 Materials and Methods
6.2.1 Patient Population
Sixty-two patients with esophageal cancer were selected for this retrospective, IRBapproved analysis. Twenty-one patients were deemed unfit for the study for various reasons.
Each patient underwent placement of a VISICOIL™ (RadioMed Corporation, an IBA Company,
Bartlett, TN) 10 mm x 0.75 mm gold fiducial marker at the inferior and superior borders of the
tumor and received 3D PET/CT prior to Radiotherapy (RTx). Patients receiving only one fiducial
marker were not included in this study. Refer to Table 6.1 for patient statistics and
characteristics. Twenty patients received fiducials pre-PET/CT and 21 patients received
fiducials post-PET/CT. In cases where patients underwent fiducial placement post-PET/CT,
planning CTs were used to delineate the location of the fiducial marker. 3D planning CTs were
imported from the Pinnacle treatment planning system (TPS; Version 9.8 Philips Medical
System™, Fitchburg, WI). 3D PET/CT and planning CT images were imported into an image
analysis software system (Mirada RTx, Mirada Medical, Oxford, UK) for measurements.

Table 6.1 Patient Characteristics.

Characteristic

n (%)

Age (median, years)
Gender
Male
Female
Location of Tumor
Upper/Middle
Middle
Middle/Lower
Lower
GEJ/Lower
GEJ
3
MTV (median, cm )

66
32 (78.0)
9 (19.5)
1 (2.4)
3 (7.3)
2 (4.9)
30 (73.2)
4 (9.8)
1 (2.4)
22.4

6.2.2 Measurement of MTV
Patients were imaged with a GE Discovery STE PET/CT Scanner (GE Medical Systems)
at our institution. A tumor threshold was created using a background uptake method. A 3 cm
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spherical volume-of-interest (VOI) was dropped onto a homogenous uptake region in the liver.
The mean and standard deviation of the standardized uptake value (SUV) was extracted to
calculate a threshold for the tumor volume as shown in Equation 6.1.
𝑇ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 = [𝐿𝑖𝑣𝑒𝑟𝜇 + 2𝐿𝑖𝑣𝑒𝑟𝜎 ]

(6.1)

where 𝜇 is mean and 𝜎 is standard deviation. In cases where contours extended into the
stomach or the heart, a Boolean tool was used to create a conformal MTV. These difficult
contours were then physician-verified and/or edited. The fiducial was delineated on CT via an
absolute threshold for HU greater than 350. The centroid was determined as the center of mass
of the fiducial contour.

Figure 6.1 Method of determining MTV threshold for each esophageal tumor. On the fused PET/CT
image, a 3-cm spherical region is placed in center of liver to account for background uptake.

6.2.3 Measurement of Fiducial Distance
The MTV contour was specified using the above defined liver threshold method and the
axial slices were used to measure the distance between each centroid and corresponding tumor
border. This distance was defined as the number of slices between the centroid of the fiducial
and the first axial PET slice that included the MTV contour. The number of axial slices was then
multiplied by slice thickness (3.27 mm for PET/CT and 3.0 mm for planning CT) to provide the
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distance in centimeters. The distance and absolute values of the distances were recorded.
Negative values described distances where fiducials were located inferior to the MTV border for
both the superior and inferior margins of the tumor. Descriptive statistics such as: mean,
median, standard deviation, maximum, and minimum were calculated. Cases involving large
distances were investigated. The Concordance Correlation Coefficient (CCC) was used to
determine correlation between the MTV threshold and superior fiducial distance (SFD), MTV
threshold and inferior fiducial distance (IFD), tumor site and IFD, tumor site and SFD, time
between fiducial and PET/CT, patient age and IFD, patient age and SFD. Tumor site represents
the location of the tumor in the esophagus (upper, mid or distal/GE junction). The strength-ofagreement scale was as follows: CCC > 0.99: high; CCC 0.95-0.99: substantial; CCC 0.90-0.95:
moderate; CCC <0.90: poor (113).
6.3 Results
The median MTV threshold was 2.51 SUV (1.6-3.6) for all patients. For patients
receiving fiducials before undergoing PET/CT (PrePF), the median MTV threshold was 2.45
SUV (1.6-3.6). For patients receiving fiducials after undergoing PET/CT (PostPF), the median
MTV threshold was 2.6 SUV (1.8-3.4). There was not much difference in MTV thresholds
between the two cohorts. A two-tailed t-test demonstrated a p-value of 0.58 between the two
cohorts demonstrating they were not significantly different. The median relative uptake for the
liver contour was 24% (5%-79%). Refer to Table 6.1-6.3. The median distance between MTV
and fiducials was -0.3 cm (-3.90 cm – 2.70 cm) and 1.3 cm (-2.1 cm – 6.87 cm) for inferior and
superior tumor borders, respectively (Table 6.2-6.4). These values were comparable to those
from the two groups. PrePF patients (Table 6.3) demonstrated a median distance between MTV
and fiducials of -0.82 cm (-2.62 cm - 2.62 cm) and 1.64 cm (-0.33 cm – 6.87 cm) for inferior and
superior borders, respectively. PostPF (Table 6.4) patients demonstrated a median distance
between MTV and fiducials of -0.30 cm (-3.90 cm – 2.70 cm) inferiorly and 0.60 cm (-4.20 cm –
3.90 cm) superiorly. A poor strength-of-agreement (CCC < 0.90) was calculated between MTV
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threshold and superior fiducial distance (SFD), MTV threshold and inferior fiducial distance
(IFD), tumor site and IFD, tumor site and SFD, time between fiducial and PET/CT, patient age
and IFD, patient age and SFD.

Figure 6.2 Method of identifying the fiducial and marking the centroid at the inferior border of the MTV.

24 of 42 (58.5%) cases had inferior fiducials located superior to the MTV border. In 13
cases (31.7%), inferior fiducials were below the MTV border. 4 cases (9.5%) demonstrated
perfect agreement between the inferior fiducial and MTV border (all PrePF). The superior
fiducial and MTV border did not have perfect agreement in any case. In 34 cases (82.9%) as
shown in Figure 6.3b, the superior fiducial was located inferior to the MTV border. In 7 cases
(17.1%) the superior fiducial was located superior to the MTV border. Of these cases, 3 of 34
(8.8%) distances were less than 0.5 cm for the superior location and 7 of 24 (29.2%) distances
were less than 0.5 cm for the inferior location (Figure 6.3).
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Figure 6.3 Inferior discordance and superior discordance histograms. Note: For inferior discordance,
negative values denote that fiducials were located inside MTV. For superior discordance, negative values
denote that fiducials were located outside MTV.

6.3.1 Large Discordances
In 8 cases, the superior fiducial-MTV discordance was greater than 2.0 cm. Of these
cases, time between fiducials and PET ranged from 2-27 days. There was only 1 occurrence
where the superior fiducial was inferior to the MTV border (negative distance). In the case of the
patient with 6.87 cm discord (see Figure 6.4), the patient was diagnosed with extensive
esophagitis and several nodules at the gastroesophageal (GE) junction. This discord was
attributed to esophagitis. Of the 1 occurrence where the superior fiducial was superior to the
MTV border, it was the only patient with medically inoperable stage 1 cancer (2 patients had
stage 2 cancer in the cohort). The patient was diagnosed with adenocarcinoma of the distal
esophagus although the uptake was in the mid esophagus. This patient had Barrett’s
esophagus from the mid esophagus to the GE junction which may have influenced the uptake in
the mid esophageal region (Figure 6.5). There was no correlation between MTV-to-fiducial
distances greater than 2 cm and the gastroenterologist that performed the fiducial implantation.
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Figure 6.4 Case with largest discord (6.87 cm) between superior fiducial and superior MTV border.

Figure 6.5 Example of discordance between fiducials and MTV at the inferior and superior location (-4.20
cm discord between superior fiducial and superior MTV border.) The red contour represents MTV
threshold. The green dot represents the superior fiducial. The red dot is the inferior fiducial.

Table 6.2 Fiducial vs MTV Border
Superior Fiducial
MTV Threshold
Distance (cm)
(SUV)
1.28
2.51

Mean

Inferior Fiducial
Distance (cm)
-0.27

Median

-0.30

1.31

2.50

24.00%

23.55

Min

-3.90

-2.10

1.60

5.00%

Max

2.70

6.87

3.60

79.00%

SD

1.50

1.52

0.42

18.19%

1.80
107.1
0
28.21

Total
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Relative
MTV (%)
28.97%

MTV
3
(cm )
30.53

FID Pre PET
Mean

Table 6.3 FID Pre PET Fiducial vs MTV Border
Inferior
Fiducial
Superior Fiducial
MTV Threshold
Relative
Distance
Distance (cm)
(SUV)
MTV (%)
(cm)
-0.64
1.68
2.44
23.50%

MTV
3
(cm )
40.13

Median

-0.82

1.64

2.45

18.50%

34.70

Min

-2.62

-0.33

1.60

5.00%

Max

2.62

6.87

3.60

74.00%

SD

1.31

1.43

0.42

16.09%

3.00
107.1
0
33.47

FID Post
PET
Mean

Table 6.4 FID Post PET Fiducial vs MTV Border
Inferior
Fiducial
Superior Fiducial
MTV Threshold
Relative
Distance
Distance (cm)
(SUV)
MTV (%)
(cm)
-0.03
0.60
2.56
34.10%

MTV
3
(cm )
21.91

Median

-0.30

0.60

2.60

31.00%

20.60

Min

-3.90

-4.20

1.80

11.00%

1.80

Max

2.70

3.90

3.40

79.00%

74.80

SD

1.68

1.77

0.44

18.54%

18.50

6.4 Discussion
Esophageal tumors can have significant respiration-induced tumor motion. A study by
Jin et al. measured the peak-to-peak magnitudes of the motion (137). The greatest motion was
found for the distal esophagus in the cranial-caudal direction with a median distance of 5.4 mm.
Median displacements for the proximal and middle esophagus were 2.9 mm and 3.7 mm,
respectively. Interestingly, motion in the cranial-caudal direction was shown to have

the

strongest correlation with respiratory curves (138). In that particular study, motion in the cranialcaudal direction reached 13.8 mm in the lower thoracic esophagus, 7.4 mm in the middle
esophagus, and 4.3 mm in the upper esophagus. Investigators are beginning to realize the
benefit of fiducials for radiation treatment planning for cancers of the esophagus (139) and
studies have demonstrated that implantation of esophageal fiducial markers are both safe and
feasible for target volume delineation purposes on CT (139). However, to our knowledge, the

90

discordance between endoscopically-placed fiducial markers and PET MTV in esophageal
cancer has not been investigated.
A retrospective study of esophageal cancer patients treated with preoperative or
definitive chemoradiation at our institution between 2000 and 2012 demonstrated 3-year overall
survival rates of 44.8% for 3-D conformal radiation therapy (3DCRT) and 41.5% for intensitymodulated radiation therapy (IMRT) (140). The rates for that study agree well with the national
5-year relative survival rate of 17% between 2010-2012 (141-143).

In the current study,

patients were treated with radiotherapy between 2009 and 2014.
It is common practice at our institution for patients with esophageal tumors that move
with respiration to undergo fiducial placement in addition to

18

F-FDG PET/CT to facilitate

conformal delivery of a simultaneous integrated boost to the gross tumor volume (144). Our
data recently reported a 55% complete pathologic response rate, significantly higher than the
29% reported with the current standard of care CROSS regimen (145), which may be secondary
to integration of both fiducials and MTV. Indeed, it is perhaps the combination of fiducials and
MTV that may allow for precise dose painting – the treatment of tumor areas that are more
metabolically active with higher doses of radiation. This incorporation has facilitated our
confidence in dose painting the gross tumor volume to a total dose of 56 Gy in 28 fractions
simultaneously with the clinical volume dosed to 50.4 Gy while ensuring the reproducibility of
our daily image guided delivery. Focal dose escalation is of particular concern in the region of
the gastroesophageal junction where stomach filling can cause additional motion (146). The
fiducials delimit the visible endoscopic mucosal tumor burden which improves target volume
delineation in precise conjunction with daily dose delivery.

MTV, on the other hand, identifies

metabolically active tumor regions and submucosal microscopic spread of disease that may not
be visible endoscopically or on a CT image.
Although our hypothesis in this study was neither confirmed nor disproven, a robust
correlation was found between the inferior fiducial location and the border of the MTV and the
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absolute SUV values were reasonably close to commonly used values of 2.5. However, relative
SUV values were lower than the typical values of 40% of SUVmax. A study by Zhong et al.
found that an SUV cutoff of 2.5 was best to estimate gross tumor length in squamous cell
carcinoma of the esophagus using 18F-FDG PET (147). This agrees with our median MTV
threshold of 2.51 SUV.
Some cases demonstrated large areas of uptake that extended well beyond the
implanted fiducial (-4.2 - 6.9 cm). In a few instances, tumors had small MTV with large distances
between the MTV border and fiducial location. These could represent tumors that were not
FDG avid. The results demonstrated that in 81% of cases, the superior fiducial was located
below the MTV threshold. Thus, in these cases, the MTV extended above the superior fiducial
placement. This discordance could be due to inflammation or esophagitis or potentially to
disease that was not endoscopically visible. In comparison, 57% of cases the MTV extended
below the inferior fiducial. Of these cases, 3 of 34 (8.8%) were less than 0.5 cm at the superior
tumor border and 7 of 24 (29.2%) were less than 0.5 cm at the inferior tumor border. The
majority of these cases were diagnosed as distal or GE junction tumors. Thus, accurate fiducial
placement may not have been possible in these cases given the proximity of the stomach.
There was a clear indication that in most cases the MTV extended beyond the superior fiducial
and that timing of the PET before or after fiducial placement was not a significant factor.
It is unclear, however, the etiology of the discordance superiorly, with the PET/CT
showing high uptake at and above the endoscopically placed marker, potentially representing
benign secondary esophagitis such as in the setting of luminal obstruction, the presence of
malignant nodes, inflammation caused by the technical aspects of the fiducial placement itself,
or potential submucosal disease. In the case of the largest discordance, the patient had been
diagnosed prior to treatment with extensive esophagitis. According to these findings, the
incorporation of a fiducial marker inferiorly into the routine management of locally advanced
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esophageal cancer may offer accurate target volume delineation when compared with 3D
PET/CT alone.
One limitation of this study is that about half of the patients underwent PET/CT imaging
prior to fiducial implantation. Thus, the PET/CT and planning CT had to be fused, and the
fiducials and distances between fiducials and the MTV borders had to be identified and
measured. Image fusion may have led to some uncertainty (148).
6.5 Conclusion
The inferior fiducial location and MTV border for esophageal cancer had a robust
correlation. Thus, it may be prudent to incorporate an inferior fiducial in the routine management
of locally advanced esophageal cancer. The etiology of the discordance between the superior
fiducial location and MTV border could be caused by inflammation from the fiducial placement
itself, submucosal disease, or benign secondary esophagitis. Regardless of the discordance,
having both fiducials is important for image guidance, especially in cases of focal dose
escalation in tumors involving the GE junction. The factors confounding FDG uptake superiorly
need further investigation to optimize MTV delineation.
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Chapter Seven: Conclusions and Future Work
7.1

Research Outcomes
This research explored PET/CT diagnostics and treatment capabilities in lung and

esophageal cancer. The main research outcomes of this work were that:


Image Features are affected by motion, especially in tumors that move greatly
(ranging ~1-2 cm) - such as those that move with the respiratory cycle (lung
tumors located near the diaphragm).



Certain features are less affected by motion and noise. GLSZM are highly
sensitive and varied greatly with the addition of uncorrelated Gaussian noise.
This is not acceptable as an additional decision factor for clinical image analysis
for PET/CT systems with high levels of noise but it could be an advantage in low
noise situations. GLSZM features may vary significantly (more than 100 % for CT
data) with change of image texture pattern. Shape features were the least
affected by the addition of uncorrelated Gaussian noise. GLCM and RLM
features were highly sensitive to image noise (change in noise level caused
changes >100%), although not as much as for the GLSZM features.



There was discordance between endoscopically placed fiducial markers and
MTV. This demonstrates a need for both techniques synergistically in the clinic to
provide a more complete view of the tumor location.

Investigators must be aware of these effects of noise and motion on image feature
analysis and account for them to avoid false positives. Chalkidou et al. found that published
studies using image feature analysis to predict clinical outcomes had an average probability of
type-I error (false positive) of 76% (82). These false positives could be caused by tumor motion
and image noise as well as other factors that affect image features such as SUV bin
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discretization (where SUV bins are divided into equally spaced bins) and reconstruction
parameters (47, 48, 81-83). Other studies have demonstrated that particular features are
correlated with tumor volume (82). Thus, the predictive abilities of these image features are
characteristics of the tumor volume and not the features themselves (71). It cannot be
emphasized enough that investigators involved in image feature analysis, especially in a clinical
setting, must be aware of how factors such as noise and motion affect their image features. This
work highly recommends that image feature analysis for PET and CT imaging modalities be
standardized and a protocol developed for reproducibility and accuracy across institutions.
7.2

Future Work
Currently, investigators are pursuing active research correlating treatment outcomes to

image features (54, 80). One goal of image feature analysis in Radiotherapy is to identify
predictive and prognostic features and to use such features to identify optimal treatment
regimen for patients (personalized medicine). This technique will allow the Radiation Oncologist
to select the optimal treatment regimen for a patient prior to treatment thus providing the best
chance of survival and quality of life (tumor control and reduced toxicity). Esophageal cancers
will especially benefit from this technique because they are time-sensitive. An ineffective
treatment could lead to an early death. A patient’s chance of survival decreases each day an
ineffective treatment regimen is used.
The next step of our research would be to extend the noise study from Chapter 4 and
assess the sensitivity of correlated noise effects on image features. This would require access
to raw PET/CT data which was unavailable during this study due to proprietary reasons. Noise
would be added directly to the sinograms in the case of PET and then reconstructed with the
noise inherent in the image, thus providing a more accurate noise image because it more
accurately represents the stochastic effect of the random variations in photon counting for CT
and radioactive decay in PET (21, 48). The ASIM PET simulator, open-access software
developed by the University of Washington (https://depts.washington.edu/asimuw/index.html) to
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simulate emission data, attenuation correction, and noise propagation would be used to apply
correlated noise to the raw PET data (sinograms) at our institution (H. Lee Moffitt Cancer
Center).
Another interesting and potentially promising idea would look at ways to account for
motion and noise effects in image feature analysis. Vaidya et al accounted for motion in their
study of 2 NSCLC patients by applying a deconvolution algorithm – an inverse filter
compensating for blurring through a motion kernel (38). Aerts et al accounted for noise by using
data that was in its raw form, without pre-processing or normalization (84). Although a 2D study,
Ganeshan et al. removed the effects of noise in CT using image filtration, using features larger
than 4 voxels (72).
Our current research serves as a warning to investigators that image features are not
independent. They are affected by many factors that require acquisition protocol standardization
across institutions.
Another future step would be standardization of Radiomic features. This would be a
collaborative effort between many institutions and research groups. Buvat stated that feature
descriptor names, definitions, and equations vary between studies (71) which warrants the
standardization of features a necessary step toward clinical applications.
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